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The National Center for HIV/AIDS, Viral Hepatitis, 
STD, and TB Prevention (NCHHSTP) of the 
Centers for Disease Control and Prevention (CDC) 
continues to recognize the value of establishing an 
integrated approach to disease control and prevention. 
Identifying patterns and trends in the populations 
affected by more than one of the diseases within the 
purview of the center creates efficiencies at the federal 
level and helps public health practitioners at all levels 
improve upon their efforts to prevent, control, and 
treat disease.
Of the five divisions in NCHHSTP, four (i.e., the 
Division of HIV/AIDS Prevention, the Division of 
Viral Hepatitis, the Division of STD Prevention, 
and the Division of Tuberculosis Elimination) 
publish yearly surveillance reports on the infections 
and diseases in their respective programs. In 
addition to these reports, NCHHSTP published its 
inaugural 2006 Disease Profile in 2008 as a first 
step toward an integrated approach to the prevention 
of human immunodeficiency virus (HIV)/acquired 
immunodeficiency syndrome (AIDS), viral hepatitis, 
sexually transmitted diseases (STDs), and tuberculosis 
(TB). This profile not only gathered program-specific 
data into a single publication but also highlighted the 
disease trends and relationships stratified by selected 
demographic groups and risk categories. The 2007 
Disease Profile reflects NCHHSTP’s continuing 
commitment to enhancing its mission through better 
integration of center-based data and programs.
population groups. Moreover, they provide the public 
health community with information essential for 
directing prevention and control efforts. In addition, 
data from enhanced public health surveillance and 
epidemiologic studies expose relationships among 
these diseases, most notably between HIV infection 
and some STDs, hepatitis B and C, and TB. These 
relationships have implications for the prevention 
of new infection and the progression of disease. For 
example, persons who are coinfected with HIV and 
hepatitis B may be more difficult to treat and more 
likely to pass on either infection by engaging in 
risky behaviors. It is therefore important to examine 
the data for patterns and trends and identify where 
the data intersect, which can guide programmatic 
efforts for a more effective public health response. 
Ultimately, this effort will be enhanced through the 
development of a standard system that conducts 
surveillance of multiple diseases.
Data Integration
Even before NCHHSTP identified program 
collaboration and service integration as one of its top 
priorities, the center began to implement additional, 
enhanced data collection systems that were designed 
to facilitate the collection, analysis, and use o f 
integrated data. A number of these systems, at various 
stages of development and implementation, are 
described below.
Background
As evidenced by the data collected from NCHHSTP- 
established surveillance systems, millions o f persons 
in the United States are affected by HIV/AIDS, viral 
hepatitis, STDs, and TB. These disease-specific 
systems regularly receive data on new infections, 
which are used in calculating disease incidence and 
prevalence and the burden of disease among various
Recognizing the need to build upon the relationships 
identified through traditional surveillance systems 
and research, NCHHSTP’s Division of HIV/AIDS 
Prevention outlined plans for a project that would 
identify occurrences of coinfection. In 2007, the 
Medical Monitoring Project (MMP) was developed 
to collect information regarding coinfection with 
HIV. Cosponsored by CDC, the National Institutes 
of Health, and the Health Resources and Services 
Administration, the MMP was designed to increase
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Figure 1. MSM Prevalence Monitoring Project: gonorrhea, 
chlamydia, and syphilis among men who have sex with 
men, by HIV serostatus—STD clinics, 2007
understanding and knowledge regarding the 
experiences and needs o f persons who receive care 
for HIV infection in the United States. The project 
encompasses two components: a personal interview 
and medical record abstraction. These data should 
provide insight into coinfection with HIV and other 
laboratory-confirmed diseases (other STDs, TB, 
and viral hepatitis), including characteristics of the 
affected populations.
It is anticipated that the MMP will help inform HIV 
and STD prevention and control activities (e.g., 
providing increased HIV testing in areas with high 
rates of STDs and incorporating STD screening into 
HIV prevention programs) and ultimately improve 
the health of the persons affected by these diseases. 
Data obtained through MMP regarding opportunistic 
infections (including TB) that occur with HIV 
infection also can be examined to better understand 
disease relationships and to highlight additional 
opportunities for prevention (e.g., the creation of 
integrated education and screening initiatives).
Other NCHHSTP initiatives contribute to an 
integrated approach. In 1999, the Division of STD 
Prevention established the National MSM (men who 
have sex with men) Prevalence Monitoring Project 
to assess the prevalence of, and trends in, STD and 
HIV infections, including the behaviors that increase 
the risk for men who have sex with men (MSM).
The project routinely collects demographic data such 
as age and race/ethnicity, and information about 
STD symptoms from MSM attending STD clinics 
in 7-10 U.S. cities. In addition, test-result positivity is 
documented for several STDs, including chlamydia, 
gonorrhea, syphilis, and HIV infection. For example, 
in 2007, of MSM who had evidence of infection 
with one of the three reportable STDs, many were 
coinfected with HIV (Figure 1).
Another data-integration effort by the Division 
of STD Prevention is the Gonococcal Isolate 
Surveillance Project—a collaborative project 
involving selected STD clinics in various locations, 
regional laboratories, and CDC. Established in 1986 
to monitor trends in antimicrobial susceptibilities 
of Neisseria gonorrhoeae, the project collects HIV 
coinfection data, along with information on age, race/ 
ethnicity, sexual orientation, and symptoms, from men 
attending STD clinics.
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Implementation o f the STD Surveillance Network 
(SSuN) further illustrates the NCHHSTP surveillance 
activities that are being conducted to understand the 
relationships between STDs and other infectious 
diseases and related program services. SSuN was 
established in 2005 as a network of six collaborating 
state and local health departments to monitor trends 
in STDs and related risk behaviors and to respond 
promptly to emerging diseases and associated risk 
behaviors. In 2008, this network was expanded 
to include 12 geographically diverse health 
departments that conduct both STD clinic-based 
and population-based surveillance. Through SSuN, 
participating health departments obtain information 
about STDs, HIV, risk behaviors, and services 
(i.e., treatment, vaccination, HIV testing).
NCHHSTP’s Division of Tuberculosis Elimination 
also collects and compiles data in an effort to 
understand the relationships between diseases. For 
instance, because HIV-infected persons are known 
to be disproportionately affected by TB, coinfection 
data are collected through several mechanisms.
For example, the National TB Surveillance System 
collects information on reported HIV infection status 
among persons with confirmed TB for 49 states and 
the District of Columbia. Data are obtained through 
patient interviews conducted by state and local 
TB programs. Through this surveillance system, 
additional HIV-related information is collected about 
TB patients whose HIV serostatus is unknown; 
these data include whether testing was offered, 
whether testing was refused, whether testing yielded
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indeterminate or missing results, or whether data 
were missing.
disparities, particularly in terms o f sociodemographic 
characteristics other than age.
The inclusion of HIV-related questions on CDC’s 
TB surveillance data form has assisted with the 
collection and reporting o f HIV-TB coinfection data. 
Since 1993, this form has enabled public health 
practitioners at state and local levels to obtain HIV- 
testing information from patients with verified TB. 
Efforts to collect these data, as exemplified by the 
National TB Surveillance System, have facilitated 
optimal case management and have enabled the 
development of more specifically targeted TB 
screening and prevention services.
More recently, efforts to match viral hepatitis 
surveillance data with data from AIDS surveillance 
have been carried out. The Connecticut Department 
of Public Health has conducted AIDS surveillance 
since 1982 and has conducted chronic hepatitis C 
surveillance since 1994. In 2007, the two surveillance 
databases were matched to measure coinfection and 
to describe the characteristics o f these cases. In 2008, 
Oregon and Colorado followed this example and in 
collaboration with CDC, conducted similar matches. 
Methods and results from the three sites are expected 
to be published later this year.
About the 2007 Disease Profile
The 2007 Disease Profile outlines the patterns and 
trends for HIV/AIDS, viral hepatitis, STDs, and 
TB and highlights the interrelationships o f diseases 
and populations in the United States.1 Similar to the 
2006 profile, the 2007 profile is intended to raise 
awareness o f the relationships among these diseases 
and demonstrate the usefulness not only o f bringing 
together, in one report, the data from separate systems 
but also of developing new surveillance systems to 
describe populations affected by multiple diseases.
To this end, the profile includes a chapter dedicated 
to a special population currently affected by more 
than one of the diseases within the purview of 
NCHHSTP. The 2007 Disease Profile focuses on 
reproductive-aged women (i.e., those aged 15-44 
years), a population that has experienced important





Human immunodeficiency virus (HIV) is a retrovirus 
that affects the immune system o f infected persons by 
destroying T cells, a type o f white blood cell on which 
the body relies to fight infection. Although initial 
infection with HIV can result in flulike symptoms 
(e.g., fever, chills, and swollen glands) about 2 
weeks after virus transmission, HIV-infected persons 
typically have no symptoms for many years. As HIV 
infection progresses, infected persons begin to show 
signs and symptoms o f a weakened immune system; 
they often become sick with diseases that reflect 
loss of the ability of the body to fight infection (e.g., 
shingles, tuberculosis, oral or vaginal thrush, herpes 
simplex virus, and Kaposi sarcoma). When HIV- 
specific opportunistic infections or conditions develop 
or the immune system is suppressed below a specific 
level, HIV-infected persons are considered to have 
acquired immunodeficiency syndrome (AIDS).
HIV is fragile and cannot persist outside the body. 
Because the virus is mainly found in blood, semen, 
and vaginal fluid, it is not transmitted through casual 
contact. Instead, the virus is transmitted primarily 
through having sex (anal, vaginal, or oral) with 
someone infected with HIV, sharing needles and 
syringes with someone infected with HIV, and being 
exposed (as a fetus or an infant) to HIV before 
or during birth or through breastfeeding. Persons 
who receive blood, blood products, or organs from 
persons with HIV infection can also become infected; 
however, this type of transmission is now rare in the 
United States because the U.S. blood supply has, since 
1985, been routinely screened for HIV.
No vaccine is available to protect persons from 
becoming infected with HIV. However, antiretroviral 
drugs can be used to reduce the viral load of HIV in 
the body and delay the progression o f HIV infection 
to AIDS. Treatment with antiretroviral drugs can 
prolong life expectancy and quality of life. Also, the
timely use of appropriate antiretroviral regimens can 
drastically reduce the likelihood of HIV transmission 
from infected mothers to their newborn children 
and the likelihood of transmission associated with 
occupational exposure (e.g., needlesticks).
Tracking HIV/AIDS
HIV/AIDS surveillance can help inform disease 
prevention and control efforts at local, state, and 
national levels by determining the burden o f disease. 
To obtain an accurate measure o f the HIV/AIDS 
epidemic, surveillance must be conducted for both 
HIV infection and AIDS. In the absence of HIV data, 
determining the annual number o f newly diagnosed 
cases of AIDS in a specific population does not 
present a complete picture of the burden or the 
impact of the disease because many other persons 
have been infected with HIV, but symptoms have not 
yet developed.
Since recognition of the HIV/AIDS epidemic in 
1981, states have conducted AIDS surveillance 
by using a standardized, confidential name-based 
reporting system; each state removes all personally 
identifying information from each case report before 
transmitting the information to CDC’s HIV/AIDS 
Reporting System. In 1994, CDC began integrating 
HIV diagnosis reporting with AIDS reporting, and 
25 states started reporting HIV diagnoses to CDC. 
Over the years, additional states implemented HIV 
infection reporting. By 2004, all states had adopted 
some type of system enabling them to collect and 
report data on cases of HIV infection, regardless of 
whether these cases had progressed to AIDS. These 
data were reported as HIV/AIDS cases. The term 
HIV/AIDS refers to three categories of HIV diagnoses 
collectively: (1) a diagnosis of HIV infection without 
a later diagnosis of AIDS; (2) a diagnosis of HIV 
infection and then a later diagnosis o f AIDS; and 
(3) concurrent diagnoses of HIV infection and AIDS
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HIV/AIDS: Key Findings
• In 2007, a total of 42,655 new diagnoses of HIV/AIDS (i.e., HIV disease, regardless of progression
to AIDS) were made in the 34 states that had been conducting confidential name-based HIV 
infection reporting since 2003.1
• The rate of new HIV/AIDS diagnoses for 2007 in the 34 states was 21 cases per 100,000.
• In 2007, the rate of AIDS diagnoses2 was 12 cases per 100,000.
• From 2003 through 2007, the number of AIDS diagnoses decreased 62% among children aged 
<13 years.
• In 2007, 15% of the HIV/AIDS diagnoses and 19% of the AIDS diagnoses were for persons aged 
40-44 years.
• About half (51%) of all HIV/AIDS diagnoses in 2007 in the 34 states were made for African 
Americans (rate, 77 cases per 100,000). The rates of new diagnoses among other races/ethnicities 
were 35 cases per 100,000 among Native Hawaiians/other Pacific Islanders,3 28 cases per 100,000 
among Hispanics, and 9 cases per 100,000 among whites.
• The rates of AIDS cases diagnosed in 2007 in the 50 states and the District of Columbia were also 
higher among African Americans (47 per 100,000), Native Hawaiians/other Pacific Islanders
(18 per 100,000), and Hispanics (15 per 100,000) than among whites (about 5 cases per 100,000).
• From 2003 through 2007, the number of newly diagnosed AIDS cases decreased among African 
Americans, American Indians/Alaska Natives, and whites; remained stable among Hispanics; and 
increased among Asians and Native Hawaiians/other Pacific Islanders.
• About three-fourths of the cases of HIV/AIDS and of AIDS diagnosed in 2007 occurred among men.
• Men who have sex with men (MSM) and persons exposed to HIV through high-risk heterosexual 
contact (i.e., heterosexual contact with someone known to have, or to be at high risk for, HIV 
infection) accounted for 85% of all cases of HIV/AIDS diagnosed in 2007.
• From 2003 through 2007, the number of diagnosed AIDS cases decreased 14% in the northeastern
region of the United States and 5% in the South and the West.
• The number of AIDS-related deaths decreased 17% from 2003 through 2007.
• In 2007, a total of 455,636 persons in the 50 states and the District of Columbia were living with 
AIDS; this number increased steadily from 2003 through 2007.
1 CDC used surveillance data from the following states to obtain 2007 HIV/AIDS estimates: Alabama, Alaska, Arizona, Arkansas, Colorado,
Florida, Georgia, Idaho, Indiana, Iowa, Kansas, Louisiana, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Jersey, New
Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West
Virginia, Wisconsin, and Wyoming.
2 AIDS estimates for 2007 include data from all 50 states and the District o f Columbia.
3 Use caution when interpreting rates for Native Hawaiians/other Pacific Islanders because the number o f cases is low and the population group
is small.
(i.e., diagnoses o f HIV infection and AIDS within 
the same calendar month). However, by 2007 only 
39 U.S. reporting areas (34 states and five U.S.- 
dependent areas) were considered mature (i.e., they 
had collected name-based HIV infection data long 
enough to obtain accurate estimates). Therefore, for 
2007, CDC analyzed HIV surveillance data from only 
these 39 reporting areas. AIDS estimates, however,
include data from all 50 states and the District of 
Columbia.
The time that elapses between the initial diagnosis 
of HIV/AIDS cases and the reporting of cases to 
state and local health departments varies. Because 
cases reported during a given period could have been 
diagnosed before the year o f report, the estimated
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(statistically adjusted) numbers o f diagnosed cases 
are more useful than the reported numbers o f cases in 
characterizing the impact o f HIV/AIDS in the United 
States for a particular period. In this chapter, the 
data are not reported case counts; they are estimates 
resulting from statistical adjustments to account for 
reporting delays and missing risk-factor information 
(the numbers have not been statistically adjusted for 
incomplete reporting).
National Snapshot
In 2007, an estimated 42,655 new cases o f HIV/AIDS 
(i.e., HIV disease, regardless o f progression to AIDS) 
were diagnosed in 34 states; this number represents 
a 15% increase over the 37,193 cases diagnosed in
2006. The rate o f new cases o f HIV/AIDS diagnosed 
in these states in 2007 was 21 cases per 100,000. For 
AIDS, the number o f cases diagnosed in the 50 states 
and the District o f Columbia in 2007 was 35,962 
(rate, 12 cases per 100,000). The annual number 
of AIDS diagnoses declined from 2003 through 
2006 (Figure 2) but increased slightly from 2006 
through 2007.
In addition to estimating the number o f newly 
diagnosed cases of disease, CDC estimated the 
number o f persons living with HIV/AIDS and AIDS 
at the end of 2007. From 2004 through 2007, the 
number o f persons living with HIV/AIDS increased
in the 34 states: 551,932 persons were living with 
HIV/AIDS in 2007, compared with 475,688 in 
2004. The number of persons living with AIDS also 
increased. CDC estimated that in the 50 states and the 
District of Columbia, the number of persons living 
with AIDS increased from 393,200 at the end of 2004 
to 455,636 at the end of 2007.
Geographic Trends
Understanding the temporal trends and geographic 
distribution in HIV/AIDS diagnoses has been 
complicated by several factors, including state-to­
state variations in the completeness and methods 
of reporting (particularly for diagnoses of HIV 
infection). Because data on diagnoses of HIV 
infection (regardless o f progression to AIDS) have 
only recently begun to be collected routinely in many 
states, determining state or regional trends in HIV 
infection has been difficult. However, geographic 
differences and trends in the prevalence o f AIDS can 
be determined annually, as all 50 states, the District of 
Columbia, and dependent areas have been reporting 
AIDS data since the early 1980s.
AIDS data are analyzed by geographic region to 
help identify areas in need of specific public health 
interventions. CDC has estimated that during 2003­
2007, more persons in the southern United States were 
living with AIDS than in any other part of the country, 
followed by persons in the Northeast. In 2007, about
184.000 and 131,000 persons were living with AIDS 
in these regions, respectively. For several years, the 
numbers of persons living with AIDS have remained 
lower in the Midwest than in any other region. In 
2007, the rates for persons living with AIDS varied 
substantially by U.S. reporting area: the lowest rate 
for adults and adolescents (i.e., persons >13 years of 
age) was that for the U.S. dependent area of American 
Samoa (2 cases per 100,000), and the highest rate 
was that for the District of Columbia (1,751 cases per
100,000). The rates for children (< 13 years of age) 
living with AIDS also varied, ranging from zero cases 
per 100,000 in several reporting areas to 30 cases per
100.000 in the District of Columbia.
The number of persons living with HIV/AIDS 
(regardless of progression to AIDS) at the end of 2007 
has been estimated for each of the 34 states. Among 
those states, New York had the highest number o f
Figure 2. AIDS cases and deaths among adults and 
adolescents—United States and dependent areas, 
1985-2007
Year o f  d ia g n o s is  o r death 
Note: Data have been adjusted for reporting delays.
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residents living with HIV/AIDS, followed by Florida 
and Texas.
Population Trends
Race/Ethnicity, Sex, a n d  A ge
HIV/AIDS continues to disproportionately affect 
persons of some minority races/ethnicities. Half of 
all HIV/AIDS diagnoses in 2007 in the 34 states with 
mature HIV infection reporting systems were made 
for African Americans, for a rate of 77 cases per
100,000.
In 2007, the Asian/Pacific Islander category, used in 
earlier HIV/AIDS surveillance reports, was split into 
two separate groups (Asians and Native Hawaiians/ 
other Pacific Islanders). Thus, disease burden for 
2007 in some populations differs substantially from 
that described in previous reports. For instance, 
the second highest rate of HIV/AIDS was that for 
Native Hawaiians/other Pacific Islanders (35 cases 
per 100,000), followed by Hispanics (28 cases per
100.000), American Indians/Alaska Natives (13 
cases per 100,000), whites (9 cases per 100,000), and 
Asians (almost 8 cases per 100,000). Caution should 
be used in interpreting the disease rates for Native 
Hawaiians/other Pacific Islanders because the number 
of cases is low and the population group is small.
Data regarding race/ethnicity also are collected and 
analyzed for diagnosed cases of AIDS. Despite a 
downward trend from 2003 through 2007, the highest 
rate of diagnosed cases of AIDS remained that among 
African Americans (47 cases per 100,000). Native 
Hawaiians/other Pacific Islanders—persons in the 
new category—were also disproportionately affected 
by AIDS in 2007 (18 cases per 100,000), as were 
Hispanics (15 cases per 100,000) (see Figure 3 for 
percentage of cases, 1985-2007). The AIDS diagnosis 
rates for other races/ethnicities remained relatively 
low: American Indians/Alaska Natives (7 cases per
100.000), whites (5 cases per 100,000), and Asians 
(4 cases per 100,000).
In 2007, about three-fourths of all diagnosed cases 
of HIV/AIDS and of AIDS occurred among men. 
From 2004 through 2007, diagnosed cases of 
HIV/AIDS increased 18% among men and 8% among
Figure 3. AIDS cases among adults and adolescents, by 
race/ethnicity and year of diagnosis—United States and 
dependent areas, 1 9 85 -200 7
Year o f  d ia g n os is  
Note: Data have been adjusted for reporting delays. 
a Includes Aslan and Pacific Islander legacy cases.
women. During this same period, the number o f 
diagnosed cases o f AIDS decreased among both men 
and women.
In terms o f age, the number o f diagnosed cases o f 
HIV/AIDS in children (<13 years of age) decreased 
during 2004-2007; the number o f diagnosed cases in 
persons aged 30-39 years also decreased. Conversely, 
HIV/AIDS diagnoses among persons 15-29 years 
of age and 40 years of age or older increased. In 
addition, persons aged 40-44 years accounted for 
the largest percentage of diagnosed HIV/AIDS cases 
(15%) during 2007 in the 34 states with mature HIV 
infection reporting systems.
Similar age trends were observed in AIDS cases, 
including decreases in the number o f diagnosed 
cases among children. From 2003 through 2007, the 
estimated number o f newly diagnosed AIDS cases 
decreased more than 60% among children (<13 years 
of age). Of all AIDS diagnoses in 2007, 19% occurred 
among persons aged 40-44 years.
Other Considerations
Beyond race/ethnicity, sex, and age, differences in 
HIV/AIDS diagnoses are associated with additional 
factors. For instance, most of the cases of HIV/AIDS 
diagnosed in 2007 in the 34 states occurred among 
MSM and persons engaging in high-risk heterosexual 
contact (Figure 4). These two populations accounted 
for 53% and 32%, respectively, of all diagnosed 
cases of HIV/AIDS. For AIDS, the number of
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Figure 4. Transmission categories of HIV/AIDS among adults and adolescents—34 states, diagnosis during 2007
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No. = 42 ,496 No. = 31,158
Note: Data include persons with a diagnosis of HIV infection, regardless of their AIDS status at diagnosis. 
Data from 34 states with confidential name-based HIV infection reporting since at least 2003.
Data have been adjusted for reporting delays and missing risk-factor information. 
aHeterosexual contact with a person known to have, or to be at high risk for, HIV infection. 
bIncludes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
diagnosed cases remained stable from 2003 through 
2007 among MSM and men exposed to HIV through 
high-risk heterosexual contact; the estimated number 
of cases also remained stable among females who 
were exposed through high-risk heterosexual contact, 
although minor fluctuations were observed by year.
Persons who inject drugs also are affected 
disproportionately by HIV/AIDS. In 2007, about 
19% of all persons living with HIV/AIDS in the 34 
states were classified as injection drug users (IDUs). 
However, from 2004 through 2007, the number o f 
diagnosed HIV/AIDS cases decreased among female 
IDUs and among MSM who also injected drugs. From 
2003 through 2007, a downward trend in the number 
of diagnosed AIDS cases was also observed among 
IDUs (including those who also identified themselves 
as MSM).
Infants and fetuses of HIV-infected mothers are also 
at risk of HIV infection. In 2007, nearly 90% of the 
HIV/AIDS diagnoses among children were due to 
infection from their HIV-positive mothers in utero, 
at birth, or through breastfeeding.
Factors th a t Affect D isease P revalence
The typically slow progression of HIV infection 
to AIDS, along with the absence in many patients 
of symptoms associated with HIV infection, have 
challenged classic methods of determining the 
prevalence of infectious diseases. Collecting data 
regarding the true number of HIV infections is 
difficult because some HIV-infected persons have not 
yet been tested and thus have not received a diagnosis; 
others have yet to be reported to disease surveillance 
programs. Many states offer anonymous HIV testing; 
however, the results of anonymous tests are not 
reported to the confidential name-based HIV registries 
of state and local health departments. In addition, 
availability of, and access to, medical care can 
substantially affect the number of diagnosed cases in a 
specific population or geographic location. Therefore, 
the actual number of persons living with HIV/AIDS is 
likely higher than is reflected in surveillance data.
HIV/AIDS
Using Surveillance Data to Improve 
Public Health
The implementation o f integrated name-based 
HIV/AIDS reporting by state and local jurisdictions 
has now been completed. As o f April 1, 2008, all 
50 states, the District o f Columbia, and five U.S. 
dependent areas (American Samoa, Guam, the 
Northern Mariana Islands, Puerto Rico, and the U.S. 
Virgin Islands) had established name-based HIV 
infection reporting.
CDC is engaging in activities to improve the quality 
and timeliness o f HIV/AIDS data to help the agency 
reach its goal o f reducing the number o f new HIV 
infections in the United States. CDC developed 
an HIV testing algorithm that enables the further 
classification o f cases o f HIV as either longstanding 
or recently acquired. This algorithm, known as 
the serological testing algorithm for recent HIV 
seroconversion (STARHS), will enable CDC to 
more quickly discern trends in HIV incidence.1 In 
partnership with state and local health departments, 
CDC has been working for several years to develop 
and evaluate a STARHS-based surveillance system. 
In 2002, a pilot program was instituted in five U.S. 
reporting areas, and as of January 2008, a total of 
25 areas have been funded to conduct incidence 
surveillance by using the STARHS system. The 
monitoring of HIV incidence will be critical in 
evaluating progress toward reducing the number 
of new HIV infections in the United States and in 
allocating resources and evaluating the effectiveness 
of prevention programs.
1 On August 2, 2008, new incidence estimates were released using new 
technology and methodology that more directly quantify the number o f 
new HIV infections in the United States (http://www.cdc.gov/hiv/topics/ 
surveillance/incidence.htm).




Infection with viral hepatitis is characterized by 
inflammation of the liver. Although several types 
of hepatitis viruses are known to cause illness, only 
hepatitis A, B, and C (infections caused by the 
hepatitis A virus [HAV], hepatitis B virus [HBV], and 
hepatitis C virus [HCV], respectively) typically affect 
persons living in the United States.
The rates of all three types of acute viral hepatitis 
have declined substantially over the past several 
decades, largely as a result of effective public health 
interventions (Figure 5). For instance, widespread 
childhood vaccination against hepatitis A and B has 
reduced the rates of these diseases to historic lows.
In addition, the incidence of acute hepatitis C has 
declined over 80%, in part because of efforts to ensure 
blood safety through the testing of the U.S. blood 
supply and the delivery of behavioral interventions 
for injection drug users (IDUs). Despite these 
achievements, cases of acute viral hepatitis remain 
common, particularly among persons in specific 
populations (e.g., IDUs, men who have sex with men 
[MSM], international travelers, and persons with 
multiple sex partners) (Figure 6). Chronic HBV and 
HCV infections are a major cause of liver cirrhosis 
and cancer, which affect millions of persons living in 
the United States.
Tracking Viral Hepatitis
Each week, cases of acute viral hepatitis are reported 
to CDC through the National Notifiable Disease 
Surveillance System, an infectious disease tracking 
system that is used by health departments in all 
50 states, the District of Columbia, and several 
U.S. territories. Additional data on cases of acute 
viral hepatitis have been collected through sentinel 
surveillance projects, including the Sentinel Counties 
Study of Acute Viral Hepatitis (1982-2006) and the
Figure 5. Incidence of acute hepatitis A, B, and C— United 
States, 19 82 -2 0 0 7
Year
a Non-A, non-B hepatitis became a reportable disease In 1982; until 1995, 
acute hepatitis C was reported as acute hepatitis non-A, non-B. 
b Numbers and rates for hepatitis C/non-A, non-B hepatitis were unreliable 
for 1982-1991 , reflecting the erroneous reporting of chronically infected 
persons as acute cases that occurred when testing for antibody to hepatitis C 
virus (anti-HCV) first became widely available. 
c Excludes cases from New York City; data were not available for 
1985-1986.
d Excludes hepatitis cases from New Jersey and Missouri for 2001. 
e Excludes cases from Missouri for 2002-2003. 
f Excludes cases from Arizona for 2006.
g Excludes cases from District of Columbia; data were not available for 2007.
Data source: National Notifiable Diseases Surveillance System, 1982-2007.
Figure 6. Selected epidemiologic characteristics among 
persons with acute hepatitis A, B, and C—United States, 
2007
Injection Homosexual M ultiple International Suspected Food 
Drug Use Activity Among Sex Partners Travela or Waterborne 
Males Outbreak0
Note: Percentage of persons that reported exposure (numerator) was based 
on the total number of persons that responded, either positively or 
negatively, to the specific exposure category (denominator).
aPersons with hepatitis B and C were not questioned about international 




Hepatitis A: Key Findings
• In 2007, a total of 2,979 acute symptomatic 
cases of hepatitis A were reported; the 
incidence rate was 1.0 case per 100,000, the 
lowest ever recorded. After underreporting 
was taken into account, this rate represents 
approximately 25,000 new hepatitis A virus 
(HAV) infections.
• In 2007, among the acute cases of hepatitis 
A reported with an identified risk factor, 
most were attributed to persons in specific 
populations at high risk: international 
travelers, men who have sex with men 
(MSM), injection drug users (IDUs), and 
persons in close contact with infected 
persons.
• In 2007, international travel was the most 
frequently reported risk factor for acute 
HAV infection (18%).
• Rates of acute hepatitis A among American 
Indians/Alaska Natives declined from 61.0 
cases per 100,000 in 1995 to 0.5 case per
100,000 in 2007.
Emerging Infections Program Enhanced Hepatitis 
Surveillance Activities (2005-present).
Surveillance of acute viral hepatitis provides data that 
can be used to (1) guide population-specific efforts to 
prevent new infections, (2) evaluate the effectiveness 
of these interventions, and (3) identify infected 
persons so that they can be provided with care and 
treatment services.
Using Surveillance D ata to  Improve 
Public Health
The surveillance data on hepatitis A, B, and C 
in the United States are useful for determining 
the burden of acute disease within specific 
populations, which, in turn, can inform public 
health interventions and ultimately improve 
health. For instance, hepatitis A surveillance 
data were instrumental in developing vaccine 
recommendations in the United States, such 
as hepatitis A vaccine recommendations for 
international travelers.
Data demonstrating both ongoing transmission of 
hepatitis B among unvaccinated adults who engage 
in high-risk sexual behaviors and low vaccine 
coverage in this population prompted the Advisory 
Committee on Immunization Practices and CDC to 
publish new guidelines in 2006 recommending that 
all adults in settings serving persons at risk (e.g.,
STD and HIV prevention centers and correctional 
facilities) receive hepatitis B vaccine. Surveillance 
data, together with data from maternal hepatitis B 
virus screening programs, led in 2005 to revising the 
recommendations regarding case management for 
infants in order to more effectively prevent perinatal 
transmission of hepatitis B virus infection. In addition, 
acute hepatitis C surveillance has detected HCV 
transmission in outpatient care settings, leading 
to public health investigations and interventions. 
Likewise, public health prevention efforts aimed at 
reducing needle sharing and other risky behaviors 
among IDUs have led to lower rates of acute hepatitis 
C in this population. In the future, surveillance 
systems that are integrated and more comprehensive, 
such as those that include tracking of both acute and 
chronic viral hepatitis infection, will help identify 
additional, previously undetected patterns of disease 
and better evaluate public health prevention programs.
About Hepatitis A
Infection with HAV can cause acute illness 
characterized by tiredness, loss of appetite, nausea, 
abdominal discomfort, dark urine, clay-colored bowel 
movements, and jaundice (i.e., a yellowing of the 
skin and eyes). Children typically are asymptomatic 
or have milder symptoms than those in adults. Unlike 
HBV and HCV infections, HAV infections are not 
chronic. This disease is spread primarily through the 
ingestion of food or water that has been contaminated 
with the fecal matter of someone who is infected and 
through close, personal contact. Casual contact with 
an HAV-infected person is not usually associated with 
disease transmission.
Hepatitis A can be prevented through the use of 
the hepatitis A vaccine, which has been available 
since 1995. The hepatitis A vaccine is recommended 
for use in specific populations, including MSM,
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IDUs, children at age 1 year, and persons traveling 
to countries where HAV infection is common. In 
addition to the vaccine, immune globulin can be 
administered to provide short-term protection against 
this virus.
National Snapshot
Anyone can be infected with HAV through common- 
source outbreaks (i.e., those involving multiple 
patients who were exposed to the virus through the 
same source, such as contaminated food) or as a result 
of an isolated event (e.g., exposure to an infected 
household member). Data from the National Health 
and Nutrition Examination Survey show that about 
one-third of persons living in the United States have 
been infected with HAV at some time.
In the United States, hepatitis A rates have varied 
cyclically, peaking approximately every 10-15 
years; the most recent peak in morbidity was in 
1995. The incidence of hepatitis A began to decline 
in 1995, after the introduction of licensed hepatitis 
A vaccines in the United States and the issuance 
in 1996 of the first public health recommendations 
for the use of vaccine in preventing transmission of 
HAV infection. In 2007, after 11 years of vaccine 
use, about 2,900 acute cases of hepatitis A were 
reported, for a historically low rate of 1.0 case per
100,000. Because many infections go unreported 
and others are asymptomatic, CDC estimated that
25,000 new infections occurred in 2007, most 
of them in groups at high risk, including MSM, 
IDUs, international travelers, and close contacts of 
infected persons.
Geographic Trends
The rates of hepatitis A have varied by U.S. 
geographical region but have been highest in 
western states. However, the rates in these states 
began to decline after CDC recommended in 1999 
that states with elevated rates implement routine 
childhood vaccination; the 2007 rates in these states 
were comparable with those in other regions of 
the country.
Race/Ethnicity, Sex, a n d  A ge
Some racial/ethnic populations have been affected 
disproportionately by HAV infection: the highest 
rates have been those for American Indians/Alaska 
Natives and Hispanics (Figure 7). However, the rates 
among American Indians/Alaska Natives began to 
decline dramatically in the mid-1990s (from 61.0 
cases per 100,000 in 1995 to 0.5 case per 100,000 
in 2007)—a reduction that can largely be attributed 
to the availability of the hepatitis A vaccine. The 
2007 rates of hepatitis A among American Indians/ 
Alaska Natives were comparable with the rates for 
other racial/ethnic populations. From 1997 to 2007, 
the hepatitis A rate among Hispanics decreased 94% 
(from 24.1 cases per 100,000 in 1997 to 1.4 cases per
100,000 in 2007). Further, the 2007 rate for Hispanics 
approached the rates for persons who were not 
classified as Hispanic.
Population Trends
Figure 7. Incidence of acute hepatitis A, by race/ethnicity 
and year— United States, 19 90 -200 7
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Surveillance data, stratified by sex, also are used to 
determine the yearly rates of hepatitis. The rates of 
hepatitis A have typically been higher among males 
than females; in fact, during 1996-2002, rates among 
males were almost twice those among females. 
Although the 2007 rates for males (1.1 cases per
100,000) were higher than those for females (0.9 case 
per 100,000), the rates for males had, since 2002,
120
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• In 2007, a total of 4,519 cases of acute 
hepatitis B were reported to CDC; after 
underreporting was taken into account, the 
estimated number of new infections was
43,000.
• In 2007, the rate of reported acute hepatitis 
B cases was 1.5 cases per 100,000, the 
lowest ever recorded.
• According to data from multiple sources, 
including the National Health and Nutrition 
Examination Survey, 800,000 to 1.4 
million persons in the United States are 
chronically infected with hepatitis B virus.
• During 2000-2007, the rates of acute 
hepatitis B were higher in the South than in 
the Midwest, the Northeast, or the West.
• In 2007, the rate of acute hepatitis B 
among African Americans remained 2-fold 
(2.3 cases per 100,000) the rate among 
whites (1.0 case per 100,000).
• In 2007, the male-to-female ratio of acute 
hepatitis B cases was 1.6 (1.9 cases per
100.000 among men versus 1.2 cases per
100.000 among women).
• In 2007, the highest rate of acute hepatitis 
B was that among persons 25-44 years 
of age.
• From 1990 through 2007, the rate of acute 
hepatitis B among persons younger than 25 
years decreased more than 90%.
• A large proportion of the acute hepatitis 
B cases reported during 2007 were 
attributable to high-risk sexual contact or 
injection drug use.
Hepatitis B: Key Findings
declined more than the rates for females, resulting in a 
smaller disparity by sex.
Rates also vary by age: for many years, the rates 
of hepatitis A were lower among children <5 years 
of age and adults >40 years of age compared with 
persons in other age groups. However, beginning in 
1997, the disparity in rates by age group began to 
close; by 2007, the rates of hepatitis A showed little 
variation in terms of age groups (range, 0.5 to 1.3 
cases per 100,000).
O ther C onsiderations
Rates of hepatitis A vary by other factors as well. For 
instance, persons who frequently travel to developing 
countries, where infection with HAV is common, 
are at substantial risk of acquiring hepatitis A. In 
2007, more cases of hepatitis A were associated with 
international travel (18%) than with any other risk 
factor; most of these cases occurred among persons 
who reported travel to Mexico or to Central or South 
America.
Hepatitis A continues to occur in populations at 
increased risk, such as MSM. In 2007, 11% of men 
who received a diagnosis of hepatitis A reported 
engaging in homosexual behavior (a decrease from the 
nearly 17% who reported engaging in this behavior 
during 2006). In 2007, the percentage of infected 
persons who reported sexual or household contact 
with a person infected with HAV, which has long 
been among the most frequently reported risk factors, 
was 8%.
Reported cases of hepatitis A among IDUs, a group 
that historically has been at higher risk of this disease, 
fluctuated from year to year. In 2007, 1% of reported 
hepatitis A cases occurred among IDUs; in 2004, 13% 
of these cases occurred among IDUs.
Hepatitis B 
About Hepatitis B
Infection with HBV affects the liver. Infants and 
children aged <5 years are typically asymptomatic, 
as are 50%-70% of older children, adolescents, and 
adults. The symptoms of hepatitis B are similar to 
those of hepatitis A (i.e., tiredness, loss of appetite,
nausea, abdominal discomfort, dark urine, clay- 
colored bowel movements, and jaundice). However, 
unlike hepatitis A, hepatitis B may lead to chronic 
illness, scarring of the liver (i.e., cirrhosis), liver 
cancer, liver failure, and death. HBV infection is 
transmitted when blood or other body fluid from an 
infected person enters the body of a person who is not 
infected, which can happen during unprotected sex, 
injecting drugs, or giving birth or can happen through 
daily exposures in a household. Lapses in infection
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control may result in health care-related transmission 
in hospitals and other settings.
Hepatitis B can be prevented through vaccination 
with the hepatitis B vaccine, which has been available 
since 1981. The hepatitis B vaccine is recommended 
for routine use in persons <18 years of age, all persons 
who have a recognized risk factor for infection (e.g., 
MSM, IDUs, health care workers, persons with STDs 
or multiple sex partners, and sexual or household 
contacts of infected persons), all patients in health 
care settings where a high proportion of adults have 
risk factors for HBV infection (e.g., STD/HIV testing 
and treatment facilities), and all persons seeking 
protection from HBV infection. In addition to a dose 
of hepatitis B vaccine, which is recommended for all 
infants at birth, hepatitis B immune globulin provides 
additional protection to newborns of HBV-infected 
mothers. Although hepatitis B cannot yet be reliably 
“cured,” medical management and antiviral therapy 
can prevent or delay more serious disease and death.
National Snapshot
In the United States, 800,000 to 1.4 million persons 
are living with chronic HBV infection. In 2007, more 
than 4,500 new cases of hepatitis B were reported to 
CDC; however, because many cases are not reported 
or are not detected (e.g., because of the absence 
of symptoms), CDC estimated that 43,000 persons 
were newly infected with HBV during 2007. The 
number of acute hepatitis B cases reported in 2007 
was lower than that reported for 2006 (4,519 and 
4,713 cases, respectively), and the 2007 rate— 1.5 
cases per 100,000—is the lowest ever recorded for 
this disease. Dramatic declines in the incidence of 
acute hepatitis B began in the mid-1980s, coinciding 
with the implementation of a national vaccination 
strategy to eliminate HBV transmission. Currently, 
recommendations include the universal vaccination of 
infants (beginning at birth), the prevention of perinatal 
HBV infection through routine screening of pregnant 
women and the provision of immunoprophylaxis 
to their infants, routine vaccination of children and 
adolescents, vaccination of adults in settings that 
serve adults at increased risk of HBV infection, and 
vaccination of all persons seeking protection against 
infection with HBV.
Rates of acute hepatitis B vary by U.S. geographical 
region. Prior to 2001, rates were higher in the South 
and West than in other parts of the country. Rates in 
all U.S. regions remained stable in 2006 and 2007 but 
continued to be higher in the South.
Geographic Trends
Population Trends
Race/Ethnicity, Sex, a n d  A ge
Progress has been made toward reducing health- 
related racial/ethnic disparities. Particularly notable 
has been the decline in the rate of hepatitis B among 
Asians/Pacific Islanders since 1990: by 2007, the 
rate was similar to that among Hispanics and whites. 
However, persons in specific racial/ethnic populations 
continue to be affected disproportionately by hepatitis 
B (Figure 8). Despite a decline in the incidence of 
hepatitis B among all racial/ethnic populations, the 
rate of acute hepatitis B among African Americans 
was 2-fold the rate among whites during 2007 (2.3 
cases per 100,000 versus 1.0 case per 100,000, 
respectively).
The rates of hepatitis B also vary by sex: the rate of 
acute hepatitis B has been higher among men than 
women. This trend continued in 2007, as evidenced by 
a male-to-female ratio of 1.6 (1.9 cases per 100,000 
among men versus 1.2 cases per 100,000 among 
women).
Figure 8. Incidence of acute hepatitis B, by race/ethnicity 
and year— United States, 19 90 -200 7
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• A total of 849 cases of acute hepatitis C 
were reported to CDC in 2007, for an overall 
rate of 0.3 cases per 100,000; the actual 
number of new infections (after accounting 
for asymptomatic cases and those that are 
not reported), is likely closer to 17,000.
• In 2007, an estimated 3.2 million persons in 
the United States were living with chronic 
hepatitis C infection.
• Rates of reported acute cases were highest 
among American Indians/Alaska Natives 
(0.48 case per 100,000) and lowest among 
Asians/Pacific Islanders (0.02 case per
100,000) in 2007.
• The difference in 2007 rates of acute cases 
reported among males and females (0.30 
and 0.26 cases per 100,000, respectively) 
represented a male-to-female ratio that was 
similar to the 2006 ratio.
• In 2007, 48% of persons with a confirmed 
case of acute hepatitis C reported injection 
drug use. The percentage of hepatitis C virus 
(HCV)-infected persons who reported this 
behavior ranged from 38% in 1998 to 54% 
in 2007.
Hepatitis C: Key Findings
Persons in some age groups also are 
disproportionately affected by hepatitis B. In 2007, the 
highest rate was that for persons aged 25-44 years; 
the lowest rate was that for children aged <15 years. 
The rates of hepatitis B have decreased substantially 
among persons of all ages, but because children 
now routinely receive the hepatitis B vaccine, the 
rates among younger persons have declined more 
dramatically than those among older persons. Since 
1990, the incidence of hepatitis B in children (<15 
years of age) has declined 98%, the incidence among 
young adults (15-24 years) has declined 93%. Rates 
among adults aged 25-44 years declined 79%, and 
rates among adults aged >45 years declined 62%.
Other Considerations
Beyond the considerations of race/ethnicity, sex, and 
age, hepatitis B continues to affect some populations 
more than others. Among infected persons for whom 
information about exposures during the incubation 
period was available, approximately one-third 
reported engaging in at least one risky sexual behavior 
(6% had sexual contact with someone known to have 
hepatitis B, 37% had multiple sexual partners, and 
18% engaged in homosexual activity). Injection drug 
use was reported for 15% of cases.
Perinatal (i.e., mother-to-child) transmission of 
HBV places newborn infants of infected mothers 
at increased risk of disease. A total of 83 cases of 
perinatal HBV infection were reported during 2007; 
because of incomplete testing and reporting, the 
number of cases of HBV infection in newborns is 
estimated to have been 10 times higher. In general, 
the rates of chronic infection in the United States are 
higher among foreign-born persons who emigrated 
from areas where HBV infection is endemic 
(e.g., Asia, Africa, and Eastern Europe).
Hepatitis C  
About Hepatitis C
HCV infection causes illness that affects the liver. 
This disease causes symptoms in only about 20% of 
infected persons, which are similar to those associated 
with all types of viral hepatitis (i.e., tiredness, loss of 
appetite, nausea, abdominal discomfort, dark urine,
clay-colored bowel movements, and jaundice). In 
55%-85% of infected persons, acute hepatitis C 
progresses to chronic infection. In 20% of chronically 
infected persons, liver disease develops and ultimately 
causes death in 1%-5% of cases. Alcohol abuse and 
HIV infection accelerate the progression of chronic 
hepatitis C. Like infection with HBV, HCV infection 
is transmitted when blood from an infected person 
enters the body of a person who is not infected; HCV 
may be spread through the sharing of needles during 
injection drug use and may also result from lapses in 
infection control in health care or other congregate 
living facilities (e.g., assisted living facilities). 
Infrequent sources of infection include transmission 
from mother to child during childbirth and from 
sexual contact. HCV infection is not spread through 
casual contact.
No vaccine is available to protect persons from 
becoming infected with HCV. However, several
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Figure 9. Incidence of acute hepatitis C, by race/ethnicity 
and year— United States, 19 92 -200 7
treatment options exist for those already chronically 
infected with this virus; treatment with a combination 
of two drugs (i.e., ribavirin and interferon) is successful 
in about half of all patients infected with HCV type 1 5 -|
and in 80% of those with types 2 or 3.
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National Snapshot § 3
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A total of 849 acute cases of hepatitis C were reported 
to CDC in 2007 (rate, 0.3 cases per 100,000), 
representing a slight increase over the number 
reported in 2006. However, after asymptomatic cases 
and those that are not reported are taken into account, 
the actual number of new infections is likely closer 
to 17,000. Hepatitis C in its chronic form affects Note
even more people in the United States; currently, an 
estimated 3.2 million are living with this persistent 
and often debilitating infection.
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: Per 100,000 population.
Until 1995, acute hepatitis C was reported as acute hepatitis non-A, 
non-B.
Figure 10. Incidence of acute hepatitis C, by sex and 
year—United States, 1 9 92 -200 7Geographic Trends
CDC does not examine geographic trends for acute 
hepatitis C because of the small number of cases that 
are reported each year.
Population Trends
Race/Ethnicity, Sex, a n d  A ge
Similar to the trends in the incidence of acute 
hepatitis A and B, the incidence of acute hepatitis C 
has declined (since 1992), but unlike cases of acute 
hepatitis A and B, the incidence leveled in 2004, 
and a slight upturn in acute cases of hepatitis C was 
observed during 2005-2007. Beginning in 2004, rates 
began to plateau for all racial/ethnic groups except 
American Indians/Alaska Natives (Figure 9); 2007 
rates were highest among American Indians/Alaska 
Natives (0.48 cases per 100,000) and lowest among 
Asians/Pacific Islanders (0.02 cases per 100,000). 
Although the rates of acute hepatitis C during 
1992-2007 were higher for males than females, the 
difference began to narrow in 2001 (Figure 10). In 
2007, reported rates of acute hepatitis C in males 
and females were 0.30 and 0.26 cases per 100,000, 
respectively, representing a ratio of male-to-female 
cases similar to the 2006 ratio.
Year
Note: Until 1995, acute hepatitis C was reported as acute hepatitis non-A, 
non-B.
The bars indicate the rate per 100,000 (left y axis) by sex; the line is 
the ratio (right y axis) of the incidence rate among males compared to 
that among females.
The disease burden of hepatitis C also differs by the 
age groups of infected persons. From 1992 through 
2007, the highest rates of acute hepatitis C were those 
among persons aged 25-39 years. Although rates for 
persons in this age group declined substantially during 
this period, the rate among persons in this age group 
remained the highest. Despite the downward trend, 
the 2007 rates, compared with 2006 rates, increased 
slightly among persons aged 25-39 years and 40 years
Viral Hepatitis
or older. Reports of hepatitis C in children younger 
than 15 years are rare.
Other Considerations
Hepatitis C continues to disproportionately affect 
populations at risk, most specifically those who 
engage in injection drug use. In 2007, nearly half of 
persons with acute hepatitis C reported injection drug 
use, an increase from the percentage of HCV-infected 
persons reporting this behavior during the preceding 
decade. In addition, because both HIV and HCV 
infections are transmitted through the use of injection 
drugs, at least one-third of HIV-infected IDUs are also 
infected with HCV; persons coinfected with HCV and 
HIV are more likely to experience liver damage and 
other complications as a result of HCV infection.
The perinatal transmission of HCV occurs in 
approximately 4% of infants born to infected mothers. 
This percentage increases for infants of mothers who 
are coinfected with HIV; approximately 20% of these 
newborns will become infected with HCV.
The risk of HCV transmission is low among long-term 
heterosexual sex partners of HCV-infected persons. 
However, the risk of transmitting HCV infection 
through sexual contact may be higher for other groups 
of persons; recent reports have described an increased 
incidence of HCV infection among HIV-infected 
MSM who engage in unsafe sexual practices.




Sexually transmitted diseases (STDs), including 
chlamydia, gonorrhea, syphilis, genital herpes, and 
human papillomavirus (HPV), substantially influence 
public health in the United States. These diseases 
negatively affect the lives of more than 65 million 
Americans, pose a significant economic burden, and 
contribute to other reproductive health problems 
(e.g., infertility, pelvic inflammatory disease [PID], 
and ectopic pregnancy).
Although progress has been made in the prevention, 
diagnosis, and treatment of STDs, the number of new 
infections continues to rise in specific populations. 
Approximately 19 million new cases of STDs occur 
each year, almost half of those among adolescents and 
young adults (i.e., persons aged 15-24 years).
Tracking STDs
STD surveillance data collected at national and local 
levels can be used to guide population-specific efforts 
to prevent new infections, identify infected persons, 
and ensure that persons with an STD diagnosis receive 
optimal treatment and education. Nationally notifiable 
STD surveillance data are compiled from reports sent 
by the STD control programs and health departments 
in the 50 states, the District of Columbia, selected 
cities, and U.S. dependencies.
Using STD Surveillance Data to 
Improve Health
The STD data collected through surveillance systems 
can be used to inform public health activities aimed at 
improving the detection of STDs, preventing disease 
transmission, and improving the lives of infected 
persons. In addition, understanding how activities 
aimed at improving case detection (e.g., expanded
screening practices and the use of more sensitive tests) 
affect disease rates in specific populations also can 
lead to strengthened, better focused efforts to prevent 
and control disease.
Notifiable STDs
The Council of State and Territorial 
Epidemiologists, in collaboration with CDC and 
local public health departments, has determined 
that national surveillance data should be collected 
annually for several notifiable STDs (e.g., 
chlamydia, gonorrhea, and syphilis). These data are 
analyzed to identify statistical trends in the diseases; 
however, they represent only a small proportion 
of the true burden of STDs in the United States. 
Many cases of notifiable STDs are not diagnosed, 
and other cases of STDs for which reporting is not 
mandatory (e.g., trichomonas, herpes, and HPV) are 
believed to be much more common. The following 
sections provide an overview of the chlamydia, 
gonorrhea, and syphilis data obtained through 




Chlamydia is an STD caused by the bacterium 
Chlamydia trachomatis. Although people infected 
with C. trachomatis usually are asymptomatic or 
exhibit only mild symptoms, chlamydia can cause 
substantial damage to the reproductive system of 
women. Untreated infection in women can lead to 
PID, which can cause permanent damage to the 
fallopian tubes, the uterus, and surrounding tissues. 
This damage can lead to an array of health problems, 





• Chlamydia infection remains the most 
commonly reported notifiable disease in 
the United States; in 2007, approximately
1,108,000 cases—the largest number ever 
reported to CDC for any condition—were 
reported by health departments in all 50 
states and the District of Columbia.
• In 2007, the national rate of reported 
chlamydia was 370 cases per 100,000, 
which represents a 7.5% increase from 2006. 
This increase in reported cases can at least 
partly be attributed to the availability of 
more sensitive diagnostic tests and to the 
expansion of screening efforts.
• Female adolescents and young women 
(i.e., those aged 15-24 years) remain the 
population most affected by chlamydia. In 
2007, case rates for females aged 15-19 
and 20-24 years (3,005 and 2,949 cases per
100,000, respectively) were higher than the 
rates for any other population or risk group.
• In 2007, 48% of all reported chlamydia cases 
occurred in African Americans.
• During 2007, more cases of chlamydia were 
reported among African-American women 
than women in any other racial/ethnic 
group; the rate of chlamydia among African- 
American females was more than 7 times the 
rate among white females.
• The 2007 chlamydia rate among Hispanics 
was nearly 3 times the rate among whites.
• The 2007 chlamydia rate among American 
Indians/Alaska Natives decreased 7.2% 
compared with the 2006 rate (733 cases 
versus 790 cases per 100,000).
• Approximately 7% of females 15-24 
years of age screened in family planning 
clinics and in selected prenatal clinics in 22 
states and Puerto Rico tested positive for 
chlamydia.
• With the exception of the rate for 
American Indians/Alaska Natives, 
chlamydia rates increased in all racial/ 
ethnic groups in 2007.
Chlamydia is the most commonly reported 
notifiable disease in the United States, and it is 
the most commonly occurring bacterial STD.
During 2007, health departments in all 50 states 
and the District of Columbia reported more than 
1 million cases of chlamydia—a 7.5% increase 
over the number of cases reported during 2006. 
From the late 1980s (when public programs for the 
screening and treatment of chlamydia in women 
were established to avert cases of PID and related 
complications) through 2007, the rates of reported 
chlamydia infections among women increased 
every year. The continued increase in chlamydia 
case reports in 2007 most likely reflects a continued 
increase in screening for this infection, but it may 
also reflect a true increase in morbidity.
Geographic Trends
Historically, chlamydia rates have varied by U.S. 
geographic region. For the years 1998-2007, rates 
were similar in the Midwest, the West, and the South; 
rates were lowest in the Northeast. During 2006­
2007, reported cases increased in all regions.
State-based chlamydia surveillance for 2007 revealed 
rates ranging from 156 (New Hampshire) to 745 
cases per 100,000 (Mississippi). When cases were 
examined by metropolitan statistical area (MSA), the 
rate of chlamydia increased from the end of 2006 
through the end of 2007 in the majority of the 50 most 
populated MSAs.
Population Trends
Race/Ethnicity, Sex, a n d  A ge
From 2006 through 2007, chlamydia rates increased 
for all racial and ethnic populations except American 
Indians/Alaska Natives (Figure 11). Rates were 
highest among African Americans; the chlamydia 
rate in this population was more than 8 times the 
rate among whites (1,399 and 162 cases per 100,000, 
respectively, in 2007).
Surveillance data reveal that chlamydia reports also 
vary substantially by sex. The rates of reported
2007 Disease Profile
Figure 11. Chlamydia rates, by race/ethnicity— United 
States, 1 9 98 -200 7
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chlamydia infections in women are 3 times the rate 
of infection in men. Recent increases in reported 
cases can be attributed to expanded efforts to screen 
women for chlamydia, more sensitive tests, and more 
complete national reporting, but they may also reflect 
a true increase in morbidity. Highly sensitive tests, 
which have been used for the past several years, 
can be used to diagnose chlamydia noninvasively in 
symptomatic and asymptomatic men and women, 
resulting in increased detection of chlamydia 
infections. This increase is partially reflected in the 
2007 data, which reveal a nearly 47% increase in 
the rate of chlamydia reported during 2003-2007 
among men and a 20% increase among women for 
the same period.
Among females, the highest rates of reported 
chlamydia infection in 2007 were those among 
adolescents and young adults (3,005 cases and 2,949 
cases per 100,000 females for those aged 15-19 and 
20-24 years, respectively) (Figure 12). Increased 
rates in this population also likely reflect increased 
screening efforts. Among men, the highest rate was 
among those 20-24 years of age.
Other Considerations
Several surveillance efforts are being conducted to 
ascertain information about chlamydia in specific 
populations, particularly among populations that 
are known to be affected disproportionately by this 
disease. For instance, the National Job Training 
Program has been screening its entrants for 
chlamydia since 1990. This effort has enabled the 
collection of data for this population of economically
disadvantaged persons aged 16-24 years, which can 
be used to help inform and improve public health 
interventions. According to National Job Training 
Program data, the state-specific median prevalence of 
chlamydia among females in 2007 was approximately 
13%. The state-specific median prevalence among 
males was approximately 7%.
The Infertility Prevention Project is a screening 
program implemented in all 10 U.S. Department 
of Health and Human Services regions. As part of 
project activities, data are collected on chlamydia 
infections in groups at increased risk of STDs such 
as persons entering juvenile and adult corrections 
facilities. Overall, the data collected by participating 
juvenile detention and adult corrections facilities in 
2007 reveal that for almost all age groups, females are 
more likely than males to test positive for chlamydia. 
In participating juvenile detention facilities across 
the country, substantial percentages of females aged 
12-18 years tested positive for this STD (facility- 
specific median, 14.3%). Data from participating 
corrections facilities for adults also reveal a high 
percentage of positive chlamydia test results among 
females (facility-specific median, 9.7%), a percentage 
that decreases with age.
Because chlamydia can negatively affect fertility 
and prenatal health, the Infertility Prevention Project 
also collected data from family planning and prenatal 
care clinics. These data revealed that a substantial 
percentage of females aged 15-24 years tested 
positive for chlamydia in 2007 (state-specific median,
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Figure 13. Chlamydia among females aged 15 -2 4 , tested in family planning clinics—United States and outlying areas, 2007
Puerto Rico 7.7
Note: Data not available for District of Columbia in 2007.
Includes states and outlying areas that reported chlamydia positivity data on at least 500 Virgin Is. 16.8
females aged 15-24  years screened during 2007. ^  ̂
Data sources: Chlamydia Prevalence Monitoring Project (Regional Infertility Prevention Projects);
Office of Population Affairs; Local and State STD Control Programs; Centers for Disease Control 
and Prevention.
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7.4% and 6.9% in participating prenatal clinics and 
family planning clinics [Figure 13], respectively). 
Variation by U.S. geographic region as well was 
found in the number of females testing positive for 
chlamydia. Those attending clinics in the South 
were more likely to test positive for this STD than 
were those attending clinics in other regions of the 
United States.
Chlamydia infection also is monitored among men 
who have sex with men (MSM) through a prevalence 
monitoring project that focuses on MSM. This project 
includes STD clinics in 7-10 U.S. cities that report 
information from clinical visits of men who report 
having sex with men. The participating clinics tested 
most MSM (clinic-specific median, 79%) for urethral 
chlamydia in 2007; a median of 7% tested positive for 
this STD.
to the expansion of chlamydia screening activities, the 
use of increasingly sensitive diagnostic tests, and an 




Gonorrhea is a bacterial STD caused by Neisseria 
gonorrhoeae. Although persons infected with N. 
gonorrhoeae typically are asymptomatic or experience 
only mild symptoms, untreated gonorrhea can cause 
substantial health problems, particularly for women.
In men, gonorrhea can cause epididymitis and 
prostatitis, but these are rare. Untreated gonorrhea in 
women can lead to PID, which can result in infertility 
and ectopic pregnancy.
Factors Affecting Rates
Although surveillance data reveal that statistical 
trends in chlamydia vary by geographic region, 
race/ethnicity, age, and sex, it is likely that several 
other factors contribute to chlamydia prevalence. 
For instance, the increase in reported chlamydia 
infections for the years 1998-2007 can be attributed
National Snapshot
Gonorrhea is the second most commonly reported 
notifiable disease in the United States. A total of 
355,991 cases of gonorrhea were reported in 2007, 
and the overall rate was 119 cases per 100,000, 
representing a slight decrease from the 2006 rate.
0 l  2007 Disease Profile
Gonorrhea: Key Findings
• A total of 355,991 cases of gonorrhea were reported in 2007, a slight decrease from 2006.
• In 2007, rates of gonorrhea were highest in the southern region of the United States, at 156 cases per 
100,000.
• Gonorrhea isolates collected in 2007 through the Gonococcal Isolate Surveillance Project (a sentinel 
surveillance project located in 28 STD clinics) revealed that resistance to fluoroquinolones is 
increasing; almost 15% of isolates demonstrated resistance to these drugs, compared with 14% in 2006.
• Rates of gonorrhea declined nearly 22% among American Indians/Alaska Natives during 2006-2007.
• In 2007, the rate of gonorrhea among African Americans was 19 times the rate among whites.
• The 2007 rates of gonorrhea were highest among young adults aged 20-24 years; rates among persons 
in this age group were 4 times the overall rate of gonorrhea in the United States.
• In 2007, the gonorrhea rate was slightly higher among women than men, at 124 and 114 cases per
100,000, respectively.
• Only seven states and Puerto Rico reported gonorrhea rates for 2007 that were lower than the Healthy 
People 2010 objective (i.e., 19 cases per 100,000).




Note: The Healthy People 2 0 1 0  target for gonorrhea is 19.0 cases per 100,000 population.
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Geographic Trends
Rates of gonorrhea vary by U.S. geographic region 
and by county. Most of the counties with more 
than 100 cases per 100,000 were in the South 
(Figure 14). During the years 2003-2007, rates were 
highest among persons living in the southern United 
States, followed by those living in the Midwest and
the Northeast. In all U.S. regions, the gonorrhea 
rates for 2007, compared with the rates for 2006, 
remained stable.
When the 2007 data were broken down by state, 
only seven states (i.e., Idaho, Maine, Montana, New 
Hampshire, North Dakota, Vermont, and Wyoming) 
reported rates lower than the Healthy People 2010
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Figure 16. Gonorrhea rates, by sex— ünited States, 1988­
2007
objective of 19 cases per 100,000. When the data 
were examined by MSA, the overall rate among 
the 50 most populated MSAs remained essentially 
unchanged, at 129 cases per 100,000. None of these 
MSAs achieved the Healthy People 2010 objective.
Population Trends
Race/Ethnicity, Sex, a n d  A ge
Gonorrhea rates vary substantially by age and by 
racial/ethnic population. In 2007, the rate of gonorrhea 
was highest among African Americans (Figure 15); 
the rate among African-American men was 26 times 
the rate among white men, and the rate among 
African-American women was 15 times the rate 
among their white counterparts. With the exception 
of African Americans, a population for whom rates 
increased almost 2% during 2006-2007, gonorrhea 
rates declined in all racial/ethnic groups. Despite 
the decreases, however, gonorrhea rates among 
American Indians/Alaska Natives and Hispanics 
were approximately 3 and 2 times, respectively, the 
rate among whites. Among racial/ethnic groups, the 
lowest rate of this disease was among Asians/Pacific 
Islanders.
For the years 2001-2007, gonorrhea rates were 
slightly higher among women than men (Figure 16).
In 2007, the rate of gonorrhea in women was 124 
cases per 100,000; the rate among men was 114.
For both females and males, gonorrhea was reported 
more often among those in younger age groups
1988 1990 1992 1994 1996 1998 200 0  2002 2004 2 0 0 6 2 0 0 7
Year
Note: The Healthy People 2010  target for gonorrhea is 19.0 cases per 
100,000 population.
(i.e., females aged 15-19 years and males aged 20-24 
years) (Figure 17).
Several surveillance efforts are being conducted 
to gather information about gonorrhea in specific 
populations, particularly groups that are known to 
be affected disproportionately by this disease. For 
instance, the National Job Training Program has 
been screening its female entrants for several STDs, 
including gonorrhea, since 1990; since 2004, male 
entrants also have begun to be tested. This effort has 
facilitated the collection of data for a population of 
economically disadvantaged young men and women 
aged 16-24 years; these data can be used to help 
guide population-specific prevention efforts and other
Figure 17. Gonorrhea rates, by age and sex— United 
States, 2007
Figure 15. Gonorrhea rates, by race/ethnicity—United 
States, 1 9 98 -200 7
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public health interventions. National Job Training 
Program data from 2007 indicated that the prevalence 
of gonorrhea was higher among female entrants than 
among male entrants (state-specific median, 3.0% 
among females and 1.1% among males).
Other Considerations
Other surveillance efforts are being conducted to 
determine the burden of STDs, including gonorrhea, 
in specific populations. For example, as part of the 
Infertility Prevention Project, monitoring projects 
have been established to obtain information about 
gonorrhea in adolescents and adults detained in 
juvenile and adult corrections facilities (populations 
among whom STD rates are high). These projects 
have demonstrated that rates of gonorrhea are higher 
among females than among males in both types of 
correctional settings. Of adolescents detained in 
juvenile facilities and screened for gonorrhea during 
2007, 5.3% of the female adolescents and 1.0% of 
the male adolescents tested positive. Of persons in 
adult corrections facilities who were screened for 
gonorrhea, 2.9% of women and 1.7% of men were 
found to have this STD.
Prenatal and family planning clinics engaging in 
screening efforts as part of this program in 2007 
reported that the rates of women testing positive for 
gonorrhea varied only slightly from the rates reported 
during recent years; among females aged 15-24 years 
attending participating prenatal and family planning 
clinics, the median, state-specific rates of positive 
gonorrhea screening tests were 0.8% and 0.9%, 
respectively.
Gonorrhea infection also is monitored among MSM 
through the MSM prevalence monitoring project, 
which collects data from STD clinics in 7-10 U.S. 
cities. Project data from 2007 demonstrated substantial 
rates of urethral, rectal, and pharyngeal gonorrhea 
among MSM seeking care in these settings (clinic- 
based median: 8%, 7%, and 6%, respectively).
Factors Affecting Rates
Beyond population group, several other factors 
continue to be important in the prevention and control 
of gonorrhea. Drug resistance has a substantial impact 
on the treatment of persons who have gonorrhea.
Before 1999, fewer than nine quinolone-resistant N. 
gonorrhoeae isolates were reported each year through 
a national sentinel surveillance system. In recent 
years, however, this number increased dramatically; in 
2007, a total of 891 isolates (almost 15% of the total) 
collected through participating sites were quinolone- 
resistant, compared with 843 (14% of the total) in
2006 and 581 (9%) in 2005.
Trends in drug resistance can be observed by region 
and population. Since 1999, quinolone resistance 
increased each year, first in Hawaii and the Pacific 
Islands, followed by western states, and then among 
MSM. By 2006, increases also were observed among 
heterosexuals and in every region of the country; in 
2007, CDC no longer recommended fluoroquinolones 
for use in the treatment of gonorrhea and associated 
conditions, such as PID.
Changes and limitations in screening practices and 
testing also influence reported rates of gonorrhea 
and other STDs. For gonorrhea, data collected in
2007 may have been affected by a shift in reporting 
source. Reporting by STD clinics (versus other 
health care providers) has decreased. In 2002, more 
than 30% of gonorrhea cases were reported by STD 
clinics; in 2007, only 27% of cases were reported by 
these clinics, suggesting that cases of gonorrhea are 
increasingly being diagnosed in the private sector.
Syphilis: Primary and Secondary 
and Congenital
About Syphilis
Syphilis is an STD caused by the bacterium 
Treponema pallidum. This disease is characterized 
by clinical phases that are interspersed by periods 
of subclinical infection detected only by serologic 
tests. The primary stage of syphilis is marked by 
the appearance of one or more chancres, and the 
secondary, disseminated stage is often characterized 
by rash and mucous membrane lesions. Persons with 
latent syphilis are asymptomatic; if the infection 
progresses, it can lead to damage of internal organs 
(e.g., brain, nerves, and heart). Syphilis in pregnant 
women can result in the perinatal transmission of 
disease, causing congenital syphilis, which can be 
fatal to the infected fetus. Untreated congenital
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Syphilis: Key Findings
• For 2007, the overall number of primary and secondary (P&S) syphilis cases reported in the United 
States was 11,466, representing an almost 18% increase over the number of cases reported in 2006 
(9,756 cases).
• The 2007 rate of congenital syphilis (10.5 cases per 100,000 live births) represents a 15% increase over 
the 2006 rate of 9.1 per 100,000 live births.
• For congenital syphilis, 2007 rates among African Americans and Hispanics were approximately 14 
and 7 times, respectively, the rate among whites.
• Men who have sex with men (MSM) accounted for approximately 65% of the reported cases of P&S 
syphilis in the United States during 2007; an estimated 4% of cases occurred among MSM in 2000.
• In 2007, P&S syphilis rates among women were highest among those aged 20-24 years (3.5 cases per
100,000); among men, the highest rates were among those aged 25-29 years of age (14.9 cases).
• Almost half (49%) of the cases of P&S syphilis reported in 2007 occurred in persons living in the South.
• Among African Americans, the overall rate of P&S syphilis in 2007— 14.0 cases per 100,000—represents 
a 25% increase over the 2006 rate of 11 cases.
• African Americans continued to be disproportionately affected by P&S syphilis in 2007. The rate of 
reported cases in this racial group was 7 times the rate among whites. The rate for African-American 
women was 14 times the rate for white women, and the rate for African-American men was more than 
6 times the rate for their white counterparts.
• Among American Indians/Alaska Natives, the P&S syphilis rate increased 6% from 2006 through 2007 
(from 3.2 cases per 100,000 to 3.4 cases). Among Hispanics, the rate increased 23% from 2006 through 
2007 (from 3.5 cases per 100,000 to 4.3 cases).
infection can also cause developmental delay, 
seizures, and death.
National Snapshot
Although syphilis rates decreased steadily in the 
United States during 1990-2000, rates have been 
increasing since 2001 (Figure 18). For 2007, the 
overall number of primary and secondary (P&S) 
syphilis cases reported in the United States was 
11,466, representing a nearly 18% increase over 
the number of cases reported in 2006 (9,756 cases). 
Congenital syphilis rates, which prior to 2006 had 
been declining for more than a decade, increased 
15% during 2006-2007. Rates of congenital disease 
typically mirror the trends among women.
Geographic Trends
Rates of P&S syphilis vary by U.S. geographic region 
and by county. In 2007, the rates of P&S syphilis
Figure 18. Primary and secondary syphilis rates, by sex— 
United States, 19 88 -200 7
Year
Note: The Healthy People 2010  target for P&S syphilis is 0.2 case per 
100,000 population.
were above the Healthy People 2010 objective of 0.2 
cases per 100,000 in 860 counties (Figure 19). These 
860 counties (27% of the total number of counties in 
the United States) accounted for 99.9% of the total 
P&S cases reported in 2007. Since 1997, the highest 
rates of P&S syphilis have been reported in southern 
states. This trend continued for the period 2006-2007,
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Figure 19. Primary and secondary syphilis rates, by county—United States, 2007
Figure 20. Primary and secondary syphilis rates, by race/ 
ethnicity—United States, 1 9 98 -200 7
when 49% of the total number of U.S. cases occurred 
among persons living in this region. Surveillance data 
from 2007 reveal that P&S syphilis rates in the South 
increased 21% over the previous year’s rate (from 4.2 
to 5.1 cases per 100,000, respectively), a trend that 
also was observed in other U.S. geographic regions: 
P&S syphilis rates increased 31% in the Northeast 
(from 2.6 to 3.4 per 100,000), 8% in the West (from
3.7 to 4.0 per 100,000), and almost 6% in the Midwest 
(from 1.8 to 1.9 cases per 100,000), a region in which 
rates had remained stable the previous year.
Population Trends
Race/Ethnicity, Sex, a n d  A ge
P&S syphilis rates vary substantially by race and 
ethnicity and other demographic characteristics. With 
the exception of Asians/Pacific Islanders, all racial/ 
ethnic populations experienced an increase in rates 
of P&S syphilis (Figure 20); during 2006-2007, 
the greatest increase (25%) was that among African 
Americans, but increases were also observed among 
Hispanics (23%), American Indians/Alaska Natives
■5 40  -, 
I  3 2 ­
g  2 4 -0
g  1 6 -
1  8 "
% 0 -  Œ 0 ^
 American Indian/Alaska Native
 Asian/Pacific Islander
 African American
-  — —  Hispanic 
 White
1 99 8  199 9  2 0 0 0  2001 2 0 0 2  2 0 0 3  2 0 0 4  2 0 0 5  2 0 0 6  2007
Year
(6%), and whites (5%). African Americans continue 
to be disproportionately affected by P&S syphilis. 
Although the disparity in the syphilis disease burden 
between African Americans and whites has narrowed 
(from rates among African Americans that were 29 
times the rate among whites in 1999 to 7 times the 
rate among whites in 2007), rates among African 
Americans still remain disproportionately high. Health 
disparities also persist in the Hispanic and American 
Indian/Alaska Native populations: the 2007 syphilis
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rates in both populations were approximately 2 times 
the rate among whites.
Surveillance data reveal that the overall increase in 
P&S syphilis rates between 2006 and 2007 primarily 
reflects an increase in the number of cases reported 
among males, although the P&S syphilis rate for 
females also increased during this period. The 2007 
P&S syphilis rate among males was 6.6 cases per 
100,000; the rate among females was 1.1 cases, 
representing an 18% and 10% increase over 2006 
rates, respectively. The elevated rates of P&S syphilis 
among males can be largely attributed to increases in 
the number of cases reported among MSM, as 65% 
of all reported cases were in this population. The 
factors contributing to increased rates among females 
remain unclear.
P&S syphilis rates also vary by age. In 2007, P&S 
syphilis rates overall were highest among persons 
in the age group 20-44 years. When the data were 
examined by sex, the highest rate for men was among 
those aged 25-29 years, whereas the highest rate for 
women was among those aged 20-24 years.
The rates of P&S syphilis continue to vary by sexual 
orientation and race/ethnicity. Most of the cases of 
P&S syphilis occurred among MSM. Of heterosexual 
men with P&S syphilis, 60% were African American, 
19% were white, 16% were Hispanic, and 5% were of 
other races/ethnicities (Figure 21).
Figure 21. Reported cases of primary and secondary 
syphilis, by sexual orientation and race/ethnicity— United 
States, 2007
Heterosexual Men Women MSMa
Note: 21% of reported male cases with P&S syphilis were missing sex of sex 
partner information; 3% of reported males cases with sex of partner 
data were missing race/ethnicity data.
No imputation was done for race/ethnicity. 
aMSM denotes men who have sex with men.
Other Considerations
To obtain information about syphilis prevalence in 
other populations, CDC collects data in a variety of 
settings. For instance, persons entering corrections 
facilities are routinely tested for P&S syphilis; 
the blood tests used for this data-collection effort 
measure seroreactivity, which indicates either 
current or past infection with T. pallidum. In 2007, 
corrections facilities in 16 states provided serologic 
data for syphilis: among persons, aged 12-18 years, 
entering a total of 13 juvenile corrections facilities, 
females were more likely to test positive for this 
STD (state-specific median: 0.2%) than were males 
(state-specific median: 0.1%). Similarly, among 
persons detained in correctional facilities for adults, 
women were more likely than their male counterparts 
to test positive for syphilis (state-specific median: 
2.1% and 1.0%, respectively).
Syphilis surveillance data for MSM also are collected 
from the STD clinics in eight U.S. cities through the 
MSM Prevalence Monitoring Project. In 2007, of the 
79% of MSM who received a nontreponemal serologic 
test for syphilis during a visit to a participating STD 
clinic, a median of 8% exhibited seroreactivity.
Factors Affecting Rates
After reaching a low in 2000, the numbers of case 
reports of P&S syphilis in men and women are 
increasing. Syphilis is now increasingly diagnosed 
in the private sector, generating concerns about the 
effectiveness of its detection and management. The 
evolving epidemiology, changing risk groups, and 
social environments pose challenges for elimination 
and STD program activities. Moreover, public 
health services face increasing pressures from rising 
demand and decreasing financial resources; and the 
social contexts of poverty, racism, homophobia, and 
socioeconomic discrimination continue to drive the 
concentration of the disease in those who engage in 
risky sexual behaviors, those who have poor access to 
care, or both.
Other STDs of Public Health Importance
Although state and local health departments routinely 
collect and report data on a few STDs, other STDs
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continue to pose substantial public health challenges. 
For example, genital herpes and genital HPV infection 
are two STDs that have been recognized as negatively 
affecting the health of millions of persons living in 
the United States; at least 45 million Americans have 
genital herpes, and approximately 20 million are 
thought to be infected with HPV.
Genital Herpes
Herpes is an ulcerative disease caused by either herpes 
simplex virus type 1 (HSV-1) or type 2 (HSV-2), 
although most genital infections can be attributed 
to the latter. Most persons who have genital herpes 
are asymptomatic or have only minimal signs or 
symptoms. Symptoms associated with genital herpes 
include genital blisters that become ulcers as the 
disease progresses, flulike symptoms, and swollen 
glands, but many persons with genital herpes are 
less severely affected. Although HSV-1 and HSV-2 
persist indefinitely in the body of an infected person, 
symptoms tend to lessen with time.
It is believed that genital herpes infection in most 
persons has not been diagnosed. According to the 
National Health and Nutrition Examination Survey 
for 1999-2004, the seroprevalence of HSV-2 among 
persons aged 14-49 years was 17% (95% CI: 15.8­
18.3). Data obtained through the National Disease and 
Therapeutic Index, a probability sample survey of the 
clinical management practices of private physicians, 
indicate that the number of visits related to new cases 
of genital herpes has increased. Increasing numbers 
of visits related to genital herpes, as suggested by 
the survey data, may indicate increased recognition 
of infection.
HPV vaccine, Gardasil, and the Advisory Committee 
on Immunization Practices recommended the routine 
vaccination of females aged 11-12 years with three 
doses of the quadrivalent HPV vaccine. Vaccination 
also is recommended for females aged 13-26 years 
who have not been vaccinated or who have not 
completed the full series. Gardasil is formulated to 
protect against four HPV types, which together cause 
70% of cervical cancers and 90% of genital warts in 
the United States.
Several sources are used currently to monitor trends 
in HPV prevalence in the United States. Population- 
based data from the National Health and Nutrition 
Examination Survey were used to identify the 
prevalence of high-risk (associated with anogenital 
cancers) and low-risk (associated with anogenital 
warts) HPV in the civilian, noninstitutionalized 
female population in 2003 and 2004. The overall HPV 
prevalence was 26.8% among females aged 14-59 
years. Sentinel surveillance data from 2003-2005 
provided an estimated prevalence of high-risk and 
low-risk HPV types in women attending clinics in six 
U.S. cities; the high-risk HPV prevalence was 23.0%. 
Data from the National Disease and Therapeutic Index 
suggest that cases of genital warts, as measured by 
initial visits to physicians’ offices, may be increasing. 
Other projects are currently being implemented by 
CDC to monitor the impact of the HPV vaccine 
on genital warts, precursors of cervical cancer, and 
cervical cancer.
Human Papillomavirus Infection
Genital HPV infection, which can be caused by more 
than 30 strains of the human papillomavirus, usually 
is asymptomatic; however, some infected persons 
have visible genital warts and precancerous changes 
in the cervix, vulva, anus, or penis. Very rarely,
HPV infection results in anal or genital cancers.
Substantial breakthroughs in the prevention of HPV 
infection have been made in recent years. In 2006, 





Tuberculosis (TB) is an infectious disease caused 
by Mycobacterium tuberculosis, although other 
mycobacteria species (e.g., M. bovis and M. 
africanum) also can cause disease. Most commonly, 
TB is spread when the germs of persons with 
infectious TB disease are released into the air 
(e.g., through coughing, sneezing, and talking) and 
are inhaled by another person. The symptoms of TB 
disease include lethargy, weight loss, fever, and night 
sweats. TB disease can occur anywhere in the body; 
however, most disease occurs in the lungs. If the 
disease affects the lungs, other symptoms can include 
coughing, chest pain, and coughing up blood.
Latent TB infection must be distinguished from 
active TB disease. The term latent TB infection is 
used to describe infection with inactive TB germs. 
Persons that have latent TB infection have been 
exposed to the disease and have been infected but 
have no symptoms. These persons are not infectious, 
although they are at risk of the eventual development 
of active disease. In general, persons with active 
TB (or TB disease) are symptomatic, and if they 
have pulmonary or laryngeal TB, they can transmit 
the infection to others. According to the National 
Health and Nutrition Examination Survey, a group 
of health surveys conducted each year among U.S. 
populations, more than 11 million persons have latent 
TB infection. An estimated 5%-10% of persons with
ATuberculosis: Key Findings
A total of 13,299 cases of tuberculosis (TB) were reported in the United States during 2007, representing 
a 3.3% decline in cases reported during the previous year.
For the fourth year in a row, the largest percentage of TB cases (29%) occurred in Hispanics. For the 
first time, Asians (26%) matched African Americans (26%) as the second largest racial/ethnic group. 
African Americans born in the United States accounted for 45% of TB cases in U.S.-born persons and 
accounted for approximately 18% of the national case total.
Asians born outside the United States accounted for 43% of TB cases in foreign-born persons and 
accounted for approximately 25% of the national case total.
TB rates remained high among foreign-born persons in 2007; the TB case rate was 20.7 for those born in 
foreign countries compared with 2.1 per 100,000 for U.S.-born persons.
The percentage of cases in foreign-born persons continued to increase and was 58% of the national 
case total.
In 2007, 21 states reported more cases than they reported in 2006.
California, Texas, New York, and Florida accounted for 48% of the national case total.
In 2007, the case rate for adults aged >65 years was 6.8 cases per 100,000.
Of all TB cases reported in 2007 (those for which initial susceptibility testing was performed and for 
which the person had no history of TB), 1.1% were multidrug-resistant (MDR)—a slight increase over 
the 1.0% of cases reported in 2006.
In 2007, two cases of extensively drug-resistant (XDR) TB were reported. 
 /
Tuberculosis
latent infection will eventually have active TB disease. 
In addition, HIV-infected persons who also have TB 
disease are more likely to die, even with treatment.
In 2006, the most recent year for which mortality 
data are available, 644 persons died of TB disease, 
representing a rate of 0.2 deaths per 100,000.
Most persons with TB disease can be treated with 
a 6- to 12-month course of multidrug therapy; 
however, some cases are caused by organisms that 
are resistant to these medications. Multidrug-resistant 
TB (MDR TB) is TB that is resistant to at least two 
of the first-line drugs used to treat the disease (i.e., 
isoniazid and rifampin). MDR TB complicates public 
health efforts to control disease. Other cases of 
MDR TB are caused by organisms that are resistant 
not only to first-line antibiotics but also to the best 
second-line drugs—fluoroquinolones and at least 
one of three injectable drugs. This subtype of MDR 
TB, known as extensively drug-resistant (XDR) TB, 
occurs very rarely in the United States. Only 2-4 
cases of XDR TB have been reported annually for 
the years 2004-2007, whereas approximately 120 
cases of MDR TB were reported each year during 
the same time period.
Tracking TB
TB surveillance carried out at the national, state, and 
local levels can help inform prevention and control 
efforts. Each year, as part of the National Tuberculosis 
Surveillance System, all 50 U.S. states and several 
other reporting areas (i.e., the District of Columbia, 
New York City, Puerto Rico, and other U.S.-affiliated 
areas in the Pacific and Caribbean) routinely report 
new cases of TB disease to CDC. TB data are then 
examined by race/ethnicity, age, and sex to determine 
how various populations are affected by this disease. 
Data are also examined for other risk factors known 
to be associated with TB (e.g., birth in a country 
with high rates of TB or human immunodeficiency 
virus [HIV] infection, residence in correctional and 
long-term care facilities, homelessness, and drug 
and alcohol abuse). In an effort to more effectively 
monitor TB caused by drug-resistant strains, CDC 
also gathers information regarding drug susceptibility 
testing for culture-confirmed cases.
National Snapshot
The number of TB cases reported in the United States 
began to increase steadily during the mid-1980s and 
reached a peak of more than 26,000 cases in 1992 
(Figure 22). This surge was attributed to several 
factors, including the HIV epidemic, increases in 
TB cases among persons born in foreign countries, 
outbreaks in congregate settings (e.g., places where 
people reside in close proximity to one another), a 
deterioration of the TB services infrastructure, and 
the emergence of MDR TB. The implementation of 
more effective TB control programs began to reverse 
this trend in 1993: the rate of TB cases decreased 
an average of 6.6% per year from 1993 through 
2002. Although the numbers of reported TB cases 
have continued to decline in recent years, the annual 
declines since 2002 have been smaller than those 
during the previous decade. In 2007, a total of 13,299 
TB cases were reported, representing a 3.3% decline 
from the number of cases reported in 2006. The 
rate of TB (i.e., number of cases per 100,000) also 
gradually declined over the past several years, from
5.6 cases in 2001 to 4.4 cases per 100,000 in 2007.
Figure 22. Reported TB cases—United States, 1982-2007
Year
Note: Updated as of April 23, 2008.
Geographic Trends
Variations in the state rates of TB largely reflect the 
place of birth and the race/ethnicity of the people that 
reside in a specific geographic area of the country.
For instance, the rates for several years have been 
disproportionately higher among American Indians/ 
Alaska Natives, Asians, African Americans, Pacific 
Islanders, and Hispanics than among whites; therefore,
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Figure 24. TB case rates, by age group and race/ 
ethnicity—United States, 2007
the rates of disease have been higher in states with 
substantial numbers of residents who are members of 
these races/ethnicities. In 2007, rates were highest in 
Hawaii, Alaska, California, Texas, New York, and the 
District of Columbia (Figure 23). In 29 states, 50% or 
more of the 2007 TB cases occurred among persons 
born outside the United States; in 13 states, foreign- 
born persons accounted for at least 70% of cases.
Figure 23. TB case rates—United States, 2007
In 2007, a total of 26 states achieved the year 
2000 Advisory Committee on the Elimination of 
Tuberculosis interim target of 3.5 cases per 100,000, 
reflecting an overall trend of decreasing numbers of 
active TB cases and rates. However, 15 states (along 
with the District of Columbia) reported rates above 
the 2007 national average of 4.4 cases, accounting for 
67% of the national burden of disease. Despite having 
higher rates of TB, these 15 states and the District 
of Columbia have experienced decreases in annual 
disease rates since 1992.
Population Trends
Race/Ethnicity, Origin of Birth, Sex, a n d  A ge
The number of reported cases of TB in the United 
States is highest among persons of minority races 
or ethnicities (Figure 24). In 2007, 83% of the total 
number of reported cases occurred among persons 
who were Hispanic (29% of cases), African American 
(26%), Asian (26%), American Indian/Alaska Native 
(1%), or Pacific Islander (<1%). Since 2004, more
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cases of TB have occurred among Hispanics than any 
other racial/ethnic group.
When examined by rate, the 2007 surveillance data 
reveal that Asians were most affected by TB; the 
rate for this group was 26.3 per 100,000. Further, the 
highest TB rate for each age group older than 24 years 
was the rate for Asians.
The disproportionate burden of TB in minority 
races/ethnicities can be attributed to several factors; 
however, one major factor is country of birth. Persons 
born in countries with high rates of TB who receive 
a diagnosis of TB in the United States may have 
acquired TB infection, or active TB disease may have 
developed, in their country of origin. The 2007 case 
rate of TB among foreign-born persons is almost 10 
times the rate among persons who were born in the 
United States. In addition, of the total number of TB 
cases reported in 2007, 58% were among foreign-born 
persons, representing an increase from 1993, when 
29% of cases were attributable to this population. 
Although the rates of TB are decreasing among all 
groups, data from 1993 through 2007 reveal that rates 
declined less among foreign-born persons (from 34 
cases per 100,000 in 1993 to 21 cases in 2007) than 
among those born in the United States (from 7.4 cases 
in 1993 to 2.1 cases in 2007) (see Figure 25 for the 
number of cases, 1993-2007). Of the cases of TB 
among foreign-born persons, 62% occurred in persons 
born in Mexico (24%), the Philippines (12%), India
0
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Figure 25. TB cases in U.S.-born vs. foreign-born 
persons— United States, 19 93 -200 7
(8%), Viet Nam (7%), China (5%), Guatemala (3%), 
or Haiti (2%), all of which have higher background 
rates of this disease than does the United States.
In 2007, the highest percentage of cases in U.S.-born 
persons were in African Americans (45%), followed 
by whites (33%) and Hispanics (16%). TB rates 
among African Americans have declined more (from 
28.0 in 1993 to 9.3 in 2007) than the rates among 
their white counterparts (from 5.5 in 1993 to 2.4 in 
2007), even though African-American TB patients are 
more likely than whites to have risk factors associated 
with TB, including homelessness, incarceration, HIV 
infection, and a recent history of substance abuse.
In 2007, TB rates were higher among males than 
females, regardless of age, although this difference 
widened with advancing age. Among children, the 
rates for both sexes were low, at <3 cases per 100,000. 
Among persons in older age groups (i.e., >45 years 
of age), the rates for men were at least double those 
for women.
In 2007, 33% of TB cases occurred among persons 
aged 25-44 years, followed by those aged 45-64 and 
>65 years (30% and 19%, respectively). During 1993­
2007, rates declined among persons in all age groups; 
the most substantial decline (over 50%) occurred 
among persons >24 years of age.
Other Considerations
Beyond race/ethnicity, country of birth, sex, and 
age, several specific populations are known to be 
affected disproportionately by TB. For instance, the
rates of TB are higher among persons infected with 
HIV. TB occurs more frequently in HIV-infected 
persons because HIV weakens the immune system, 
greatly increasing the likelihood of progression from 
latent to active TB disease. Although 2007 data on 
coinfection were not available at the time this profile 
was published, data collected from 1993 through 
2006 (excluding California) reveal that coinfection 
with HIV and TB decreased substantially among 
persons of all age groups, particularly among those 
aged 25-44 years. In 2006, for those with reported 
HIV test results, approximately 7% of TB-infected 
persons of all ages and 12% of TB-infected persons 
aged 25-44 years were coinfected with HIV. Groups 
of TB patients at greater risk of HIV infection include 
injection drug users, homeless persons, African 
Americans, correctional facility inmates, and persons 
who abuse alcohol.
Because TB is an airborne disease (i.e., transmitted 
through the air after a patient with active disease 
coughs or sneezes), it is transmitted more efficiently 
to persons who are in close contact, for extended 
periods, with a person who has the active disease. 
Therefore, rates of TB have historically been high 
in groups of persons living in congregate settings, 
including correctional facilities, long-term care and 
residential facilities, and homeless shelters. To help 
inform TB prevention and control activities, data 
on persons in congregate settings are collected each 
year. In 2007, approximately 4% of the total number 
of reported TB cases were among persons living in 
correctional facilities, 2% were among persons living 
in long-term care facilities, and 6% were among 
persons who identified themselves as homeless.
TB rates are disproportionately high among persons 
who use illicit drugs. Although the relationship 
between TB and drug use is not completely 
understood, states routinely collect data regarding 
drug use (injected, ingested, or smoked) among 
persons with a diagnosis of TB disease. In 2007, of 
all reported TB cases, approximately 2% were among 
persons who reported having injected drugs within the 
12 months preceding TB diagnosis; 8% of reported 
cases of TB were among persons who reported having 
ingested or smoked drugs.
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Drug-resistant Tuberculosis
Drug resistance poses a challenge to public health 
efforts aimed at controlling and preventing TB 
disease. In 2007, drug resistance continued to affect 
some populations disproportionately. For instance, 
although the percentage of TB cases resistant to 
isoniazid had decreased during the preceding decade, 
the 2007 percentage of isoniazid-resistant cases in 
persons born in foreign countries remained twice the 
percentage of cases in persons born in the United 
States (9.4% versus 4.4%, respectively). Foreign- 
born persons emigrating from countries with high 
rates of MDR TB have increasingly contributed to 
the proportion of MDR TB cases in the United States. 
From 1993 through 2007, the percentage of all cases 
of MDR TB attributable to persons born in other 
countries increased from 26% (1993) to 80% (2007).
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SPECIAL FOCUS: WOMEN OF REPRODUCTIVE AGE
The 2007 Disease Profile highlights the health issues 
faced by reproductive-aged women, many of whom 
are affected by one or more of the diseases described 
in this report. In this chapter, we define reproductive- 
aged women as females who are 15-44 years of 
age. Although this age range is commonly used, it 
may vary slightly from that used in other reports 
and in other sections of this report; it does, however, 
encompass most females of reproductive age.
National surveillance data as well as data from other 
scientific studies have shown that reproductive-aged 
women, particularly those of some races/ethnicities 
(e.g., Hispanic) and within specific age subgroups 
(e.g., aged 15-19 years), bear an elevated burden 
of disease and remain in need of effective health 
interventions. Given that women in these subgroups 
continue to be affected disproportionately by more 
than one of the diseases within the purview of the 
National Center for HIV/AIDS, Viral Hepatitis, STD, 
and TB Prevention, this chapter concludes with a 
discussion of the disease-related health disparities 
faced by these women.
Diseases that affect reproductive-aged women are of 
particular interest, because many of these diseases 
can be transmitted to infants before (prenatal), 
during (perinatal), or after (postnatal) childbirth.
For example, HIV infection can be transmitted 
from mother to child not only during pregnancy 
and childbirth but also (through breastfeeding) after 
childbirth. In addition, some of these diseases may 
lead to more serious health problems. Some untreated 
sexually transmitted diseases (STDs) in women can, 
for example, result in pelvic inflammatory disease 
and infertility.
Elevated rates for some of these diseases in 
reproductive-aged women relative to other 
populations, such as men or women of other ages, 
can be attributed to several factors, including 
biological, social, and behavioral factors, and
structural and environmental factors such as 
limited access to high-quality health care. Women, 
compared with men, also are more likely to shoulder 
the burden of caring for others, including their 
children and elderly parents, and may neglect their 
own health in the process. Other factors, including 
racism and discrimination, are associated with the 
disease disparities among reproductive-aged women 
of some minority races/ethnicities or of lower 
socioeconomic status.
Understanding the effects of multiple diseases 
on the health and quality of life of reproductive- 
aged women can help to better direct prevention, 
education, and treatment efforts. Because women 
in this age group are often the primary decision­
makers in their households for health-related 
issues, it is particularly important to reach these 
women with accurate health messages. Ensuring 
that women are well informed about the prevention 
of HIV/AIDS, viral hepatitis, STDs, tuberculosis 
(TB), and other infectious diseases increases the 
likelihood that health-related messages will reach 
other populations, including men, children, and the 
elderly. The identification of overlapping patterns 
and trends involving two or more of these diseases 
may therefore facilitate a more efficient and cost- 
effective approach to improving the health of 
reproductive-aged women and, when appropriate, 
their families.
HIV/AIDS
Although men accounted for almost three-fourths 
of the estimated number of HIV/AIDS diagnoses 
in 2007 from the 34 states with long-standing 
name-based HIV infection reporting, newly 
diagnosed cases are continuing to affect women 
disproportionately in some subpopulations. In 2007, 
most of the diagnoses of HIV/AIDS in females were 
among those aged 15-44 years.
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HIV infection among women of reproductive age 
poses clinical and public health challenges. Similar to 
other diseases discussed in this chapter, HIV infection 
can be transmitted from a pregnant woman to her 
infant during pregnancy, childbirth, and breastfeeding. 
Approximately 25% of infected women who do not 
receive treatment and do not breastfeed transmit 
HIV infection to their infants during pregnancy or 
childbirth. Since the beginning of the AIDS epidemic 
in the early 1980s, AIDS has been diagnosed for more 
than 8,400 children who were perinatally infected 
with HIV; more than half of these children have died. 
Fortunately, antiretroviral therapy during pregnancy 
dramatically reduces the likelihood of mother-to-child 
transmission (from about 25% to less than 2%). This 
reduction underscores the importance of increasing the 
number of pregnant women who are tested for HIV.
Because reproductive-aged women are often the 
primary caregivers in their households, HIV/AIDS in 
this population can have far-reaching implications. 
HIV-infected women may have difficulty caring for 
their children and other family members, which can 
negatively affect the emotional and physical health 
of these persons. The social stigma associated with 
HIV infection can also affect women’s health-related 
behaviors, including the decisions to get tested, seek 
treatment, and disclose their HIV serostatus to their 
sex partners.
CDC is involved in several activities aimed at 
preventing and controlling HIV/AIDS in women of 
reproductive age. For instance, the agency developed 
an initiative, Advancing HIV Prevention: New 
Strategies for a Changing Epidemic, that focuses on 
the following four major prevention strategies, all of 
which are applicable to reproductive-aged women:
(1) making HIV testing a routine part of medical care,
(2) using new models for diagnosing HIV infection 
outside traditional medical settings, (3) preventing 
new infections by working with HIV-infected persons 
and their partners, and (4) decreasing mother-to- 
child HIV transmission. CDC also has worked
to identify effective HIV/AIDS interventions for 
groups of women who are at higher risk of disease, 
including young African-American women, pregnant 
women who live in inner-city neighborhoods, and 
women who are socioeconomically disadvantaged.
In addition to these initiatives, CDC has supported 
grassroots projects aimed at preventing and 
controlling HIV/AIDS among women by awarding
HIV-prevention funding to 22 community-based 
organizations. Further, the agency supports local 
demonstration projects that offer HIV testing to 
female partners of HIV-infected men, particularly 
in communities with large numbers of African 
Americans and Hispanics.
To reduce the incidence of perinatal HIV 
transmission, CDC has conducted enhanced perinatal 
surveillance activities for more than a decade. As 
part of those surveillance activities, CDC set several 
goals for reducing perinatal HIV transmission in 
areas with high prevalence. These goals are (1) to 
monitor the implementation of the recommendations 
of the U.S. Public Health Service for counseling 
and voluntary testing of pregnant women, the use of 
antiretrovirals to prevent perinatal HIV transmission, 
and the effect of implementation on the trends of HIV 
disease among children; (2) to establish a surveillance 
system to collect data that enable states to respond to 
selected requirements of the Ryan White CARE Act; 
and (3) to assist with timely evaluation of perinatal 
prevention efforts.
Understanding the patterns and trends in HIV 
infection among all reproductive-aged women, 
including those who are pregnant, is important 
for ensuring that these women receive prevention, 
education, and treatment, all of which will not 
only help improve the health of women in this age 
group but protect their partners and children from 
becoming infected.
Hepatitis B
Chronic hepatitis B virus (HBV) infection is a 
serious problem among women of childbearing age. 
Although commonly unaware of their infections, 
women with chronic HBV infection can transmit the 
infection to their infant at birth. The infant’s risk of 
HBV infection after mother-to-child transmission 
(perinatal transmission) is 70%-90% if the mother is 
positive for both hepatitis B surface antigen (HBsAg) 
and hepatitis e antigen (HBeAg). The infant’s risk 
of HBV infection is less than 10% if the mother 
is positive only for HBsAg. Even if a child is not 
infected at birth, the child remains at risk of HBV 
infection through long-term interpersonal contact 
with an infected mother. According to some studies, 
a child’s risk of HBV infection is approximately 40%
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Figure 27. Incidence of acute hepatitis B among females 
aged 1 5 -4 4  years, by race/ethnicity—United States, 
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by 4 years of age simply by living in a household 
with a chronically infected person. Furthermore, the 
infant’s risk of progression of the infection to chronic 
HBV infection is inversely related to his or her age at 
the time of infection. In almost all infected infants and 
a large proportion of infected children, the infection 
progresses to chronic HBV infection. By contrast, the 
infection progresses to chronic infection in only 0.5% 
to 2.0% of infected adults. Infants and children with 
chronic HBV infection are thus at the highest risk of 
liver failure, cirrhosis, and liver cancer, any of which 
may cause death.
Acute HBV infection is a reportable disease in all 50 
states. States report cases of acute infection, including 
HBV, to CDC by using the National Notifiable 
Disease Surveillance System. The 2007 data for 
females aged 15-44 years showed a higher incidence 
of acute HBV infection among those aged 25-34 
years (2.2 cases per 100,000) and 35-44 years (2.3 
per 100,000) than among those aged 20-24 years 
(1.3 per 100,000) and those aged 15-19 years (0.4 per
100,000) (Figure 26). However, the incidence of acute 
HBV infection has declined for all age groups since 
the introduction, in the mid-1980s, of a comprehensive 
strategy for eliminating HBV infections in the United 
States. The decline during 1998-2007—greatest for 
the youngest age group (15-19 years) and least for 
the oldest age group (35-44 years)—suggests a cohort 
effect that is consistent with the ages at which females 
are most likely to be vaccinated.
The 2007 race/ethnicity data from the National 
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a higher incidence of acute HBV infection among 
African-American women (3.1 cases per 100,000), 
followed by American Indian and Alaska Native 
women (1.75 per 100,000) (Figure 27). The lowest 
incidence was that among Hispanic women: 0.8 cases 
per 100,000. In terms of trends, the highest incidence 
in 1998 was that for Asian and Pacific Islander 
women (9.7 per 100,000), but by 2007, the incidence 
among these women showed the largest decline (0.9 
cases per 100,000). White women experienced the 
smallest decline (45%) from 1998 through 2007, but 
the rate among white women was the lowest in 1998 
(2.3 per 100,000), and it remained low in 2007. By 
2007, the rate among African-American women had 
declined from 8.4 per 100,000 in 1998.
Figure 26. Incidence of acute hepatitis B among females 
aged 1 5 -4 4  years, by age group— United States, 1998­
2007
Year
Note: Per 100,000 population.
Among females aged 15-24, 25-34, and 35-44 
years, the most commonly reported risk behavior was 
multiple sex partners (47.5%, 35.8%, and 37.4%, 
respectively). Injection drug use was the second 
most commonly reported risk behavior, followed 
by sexual contact with a person known to be HBV- 
positive. Sexual contact with an HBV-infected person 
differed little in terms of age group. The prevalance 
of injection drug use was higher among females aged 
25-34 years (26.4%) than among those aged 15-24 
years (14.3%) or those aged 35-44 years (15.2%).
Another factor that influences the incidence and 
prevalence of HBV infection is country of origin. 
Data from studies of foreign-born U.S. residents 
indicate that HBsAg seroprevalence corresponds to
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HBV endemicity in their country of origin. That is, 
chronic infection is more common in persons born in 
areas where HBV infection is endemic (notably, Asia, 
Africa, and Eastern Europe) and who immigrate to the 
United States than in those born in the United States.
The Behavioral Risk Factor Surveillance System, 
a state-based telephone survey of adults aged 18 
years or older, also collects hepatitis-related data on 
reproductive-aged women. According to the 2006 
survey, of more than 65,000 women of childbearing 
age (18-44 years), approximately 52.2% reported 
receiving the recommended three-dose hepatitis B 
vaccination, 6.5% reported engaging in at least one 
behavior associated with increased risk of HBV 
infection, and 4.1% were pregnant at the time of the 
survey. Overall, the women who received the three- 
dose vaccine series did not differ by race/ethnicity.
Of pregnant women, 53.5% (95% CI = 49.4-57.4) 
reported receipt of the three-dose hepatitis vaccine 
series. These data demonstrate the need to educate 
women of childbearing age, particularly those who 
are at increased risk of HBV infection, and pregnant 
women to ensure that they are properly vaccinated 
against HBV infection.
CDC’s strategy for eliminating HBV infection among 
infants, children, and adolescents in the United 
States includes several recommendations. These 
include the universal screening of pregnant women 
for HBsAg during each pregnancy and the provision 
of immunoprophylaxis to infants born to infected 
mothers, including hepatitis B vaccine and hepatitis 
B immune globulin during the first 12 hours after 
birth. In addition, CDC recommends completion of 
the hepatitis B vaccine series and post-vaccination 
testing for immunity; routine vaccination of all infants 
with the hepatitis B vaccine series, with the first 
dose administered at birth; and completion of the 
hepatitis B vaccine series for all unvaccinated persons 
<19 years of age.
To promote strategies to prevent perinatal HBV 
transmission, CDC currently awards immunization 
funds to 64 state and local health departments. In 
2006, an estimated 25,000 U.S. women screened 
during prenatal care showed signs of HBV infection 
(i.e., tested positive for HBsAg). Of babies born to 
HBV-infected women, approximately 98% received 
the necessary shots at the recommended times to 
prevent mother-to-child transmission. Although
improvements in the prevention of HBV transmission 
from mothers to infants have been documented, 
gaps remain in the identification and public health 
management of HBsAg-positive pregnant women 
and their infants, as well as in the case management 
of the infants and household and sexual contacts. 
HBV-infected mothers need care to reduce the 
risk of premature death as a result of liver disease. 
Some infants of HBV-infected mothers do not 
receive recommended interventions: the result is that 
chronic HBV infection develops in approximately 
800 children each year. Other family members are 
at increased risk of infection and should receive 
HBV screening and vaccination. To maximize the 
prevention of HBV infection, emphasis is placed on 
provider education to increase the number of pregnant 
women who are screened, program evaluation and 
capacity building to improve case management, and 
the implementation of electronic laboratory reporting 
to improve surveillance.
Strategies to prevent HBV infection, combined 
with case management procedures, are expected to 
contribute to the elimination of HBV infection in 
the United States. Surveillance of viral hepatitis, 
including acute and chronic infection, is a crucial part 
of this effort.
Sexually Transmitted Diseases
Reproductive-aged women, particularly those aged 
15-24 years and those of minority races or ethnicities 
are affected disproportionately by several STDs. 
Unlike infected men, infected women can experience 
significant adverse health effects for decades.
In 2007, more than 800,000 cases of chlamydia 
infection in women were reported, making it the most 
commonly reported disease in the United States. 
Among states and territories participating in the 
Infertility Prevention Project (screening in selected 
prenatal clinics) in 2007, the percentage of female 
patients aged 15-24 years who tested positive was 
especially striking: range, 2.0% to 20.7% (Figure 28). 
Although the reported case rate for women was 
nearly 3 times the rate for men, this disparity can be 
attributed to more frequent screening for this disease 
among women. Because chlamydia in women is 
asymptomatic in up to 75% of cases, increased rates 
of chlamydia create difficulties for both prevention
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Data sources: Chlamydia Prevalence Monitoring Project (Regional Infertility Prevention Projects); Office of Population Affairs; Local and State STD Control Programs; 
Centers for Disease Control and Prevention
and treatment. Untreated chlamydia can lead to severe 
health complications for women; for example, in 
up to 40% of infected women, untreated chlamydia 
can cause pelvic inflammatory disease, which can 
have long-term health implications (e.g., infertility 
and ectopic pregnancy). Among reproductive- 
aged women, chlamydia also increases the risk for 
additional adverse health effects, including HIV 
infection. A woman who is infected with chlamydia, 
compared with a woman who is not infected, is 3 to 5 
times as likely to become infected with HIV.
Gonorrhea is the second most commonly reported 
disease in the United States. Although rates of 
gonorrhea were similar among men and women for 
the years 2001-2007, the 2007 gonorrhea rate among 
women (approximately 125 cases per 100,000) 
remained higher than the Healthy People 2010 
objective of 19 cases per 100,000. In the states and 
territories participating in the Infertility Prevention 
Project in 2007, the percentage of females aged 
15-24 years who tested positive ranged from <1% 
to 3.9% (Figure 29). Like chlamydia, gonorrhea 
is often asymptomatic and can have severe health 
consequences, such as pelvic inflammatory disease, 
for reproductive-aged women; therefore, the
continued high rates in this population are especially 
concerning. To help control and prevent gonorrhea 
among reproductive-aged women, the U.S. Preventive 
Services Task Force recommends that clinicians 
screen all sexually active women who are at increased 
risk of gonorrhea infection, including those who 
are pregnant.
Historically, primary and secondary (P&S) syphilis 
has affected more men than women; however, rates 
among reproductive-aged women increased for the 
period 2004-2007. During 2006-2007, rates of P&S 
syphilis increased for each age subgroup within the 
broader group (15-44 years) of reproductive-aged 
women.
Chlamydia, gonorrhea, and P&S syphilis in 
reproductive-aged women have additional 
implications because these STDs can adversely affect 
the health of the pregnant woman and her newborn. 
Women infected with chlamydia can give birth to an 
infant who also is infected in the form of neonatal 
ophthalmia or neonatal pneumonia. Gonorrhea, too, 
can lead to ophthalmia in infants born to infected 
mothers. P&S syphilis in a pregnant woman can lead 
to congenital syphilis in her infant. The annual rates
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Figure 29. Gonorrhea among females aged 1 5 -2 4  years, tested in prenatal clinics, by state—United States and outlying 
areas, 2007
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Note: Includes states and outlying areas that reported gonorrhea positivity data on at least 100 women 
aged 15 to 24 years during 2007.
The District of Columbia and the fo llow ing  31 states d id not meet minimum inclusion criteria in 
prenatal clinics: A labam a, Alaska, A rizona , C a lifo rn ia, Colorado, Connecticut, Delaware, Hawaii, 
M aine, M ary land, Massachusetts, M ichigan, M innesota, M ontana, Nevada, N ew  Hampshire,
N ew  Jersey, N orth  Dakota, O hio, O regon, Rhode Island, South Caro lina, South Dakota, Texas, 
Utah, Vermont, V irg in ia , W ashington, West V irg in ia , W isconsin, and W yom ing.
Data sources: G onorrhea Prevalence M onitoring Project (Regional Infertility Prevention Projects); O ffice  of 
Population A ffa irs; Local and State STD Control Programs; Centers fo r Disease Control and Prevention
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of congenital syphilis increased substantially in 2006 
(11%) and 2007 (15%). Those increases are most 
likely related to the increased number of cases of P&S 
syphilis in women of reproductive age. The 2007 rate 
of congenital syphilis remained 10 times the Healthy 
People 2010 objective of 1.0 case per 100,000 live 
births.
As evidenced through several initiatives, CDC is 
committed to reducing the burden of these STDs 
among reproductive-aged women. CDC supports 
the Infertility Prevention Project, a collaborative 
screening program that was established in 1988 
and implemented in all 10 Health and Human 
Services regions. This project monitors the trends 
in chlamydia and gonorrhea among reproductive- 
aged women who visit one of the participating 
public clinics. To gain additional insight into the 
incidence of chlamydia among females aged 15-25 
years, CDC analyzed the 2000-2007 data from the 
Health Plan Employer Data and Information Set 
(HEDIS), reported by commercial and Medicaid 
health insurance plans; the results of this analysis 
were published by CDC in 2009.
Data from these projects have informed the 
development of targeted screening and intervention
recommendations. For instance, the elevated rates of 
chlamydia among young reproductive-aged women, 
along with the associated and far-reaching health 
complications in this population, prompted CDC to 
recommend chlamydia screening for sexually active 
females <26 years of age and older women who are at 
increased risk.
Tuberculosis
Although rates of TB in all age groups are higher for 
men than women, disease incidence differs among 
women of reproductive age. For instance, rates are 
higher among women of minority races or ethnicities 
and women born in certain foreign countries.
Health Disparities among 
Reproductive-Aged Women
Many of the diseases discussed in this chapter 
(HIV/AIDS, STDs, TB, and hepatitis B) 
disproportionately affect specific subsets of women 
within the broader focus population. The rates of 
disease in some subgroups, including women of 
minority races/ethnicities (Figure 30), younger or
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Figure 30. AIDS, hepatitis B, chlamydia, gonorrhea, syphilis, and TB among among females aged 1 5 -4 4  years, by race/ 
ethnicity— United States, 2007
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older women of reproductive age, and women born in 
certain foreign countries, are substantially higher than 
the rates of disease among reproductive-aged women 
in other demographic groups.
African-American W om en
African-American women, compared with white 
women, face significant health disparities in rates 
of HIV/AIDS, other STDs, hepatitis B, and TB. 
Several factors are associated with increased rates 
of these diseases among African-American women, 
including lack of awareness of the activities that 
place them at risk of infection. For HIV/AIDS, these 
activities include unprotected sex with multiple 
partners or with men who have sex with both men 
and women, and injection drug use; the presence 
of other STDs (which increases the likelihood of 
becoming infected with HIV if exposed to the virus)
also is associated with increased risk of HIV infection 
in these groups, because African-American women 
are affected disproportionately by several STDs. 
Likewise, HIV-TB coinfection increases the risk 
that latent TB infection will progress to active TB 
disease. Because the prevalence of HIV is high among 
African-American women, they are more likely to be 
affected by the adverse health outcomes associated 
with active TB.
For all of the diseases discussed in this profile, 
poverty is a significant social determinant of health 
for reproductive-aged women. One in four African 
Americans lives in poverty—a socioeconomic 
factor that has been directly associated with 
less frequent receipt of important health-related 
services (testing, treatment, education, and other 
types of interventions). Social and cultural trends 
and traditions also can affect transmission rates
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among African-American women of reproductive 
age. Homophobia and stigma can cause some 
African-American MSM to identify themselves 
as heterosexual or not to disclose their sexual 
orientation, which may be a factor in HIV 
transmission, particularly for African-American 
women.
In 2006, HIV disease was the fourth leading cause 
of death among African-American women aged 
25-34 years in the United States. In 2007, 65% of the 
women living with HIV/AIDS in the 34 states with 
mature HIV infection reporting systems were African 
American. In 2007, the most recent year for which 
data have been compiled, the rate of AIDS diagnoses 
for African-American women was 22 times the rate 
for white women. Of African-American women living 
with HIV/AIDS in 2007, three-fourths had been 
infected as a result of high-risk heterosexual contact 
(sex with an HIV-infected man). The second most 
common mode of transmission for this population was 
injection drug use.
Chlamydia, gonorrhea, and P&S syphilis also affect 
disproportionate numbers of African-American 
women. The rates of these three STDs among 
African-American females aged 15-44 years are 
about 6, 13, and 10 times, respectively, the rates 
among their white counterparts. For chlamydia, the 
2007 rate among African-American females aged 
15-34 years reflects a substantial increase over 
the 2006 rate. For gonorrhea, the 2007 rate among 
African-American females in this age group reflects 
a slight increase over the 2006 rate. For P&S 
syphilis, the 2007 rate was higher than in earlier 
years for all age subgroups of reproductive-aged 
women, except for the subgroup 15-19 years: for 
this subgroup, the rate remained stable.
In 2007, the incidence of acute hepatitis B among 
reproductive-aged women was highest among 
African-Americans: 3.1 cases per 100,000 in 2007. 
Although African-American women continue to be 
unduly affected by this disease, rates have declined 
63% since 1998.
African-American women of reproductive age also 
are disproportionately affected by TB. In 2007, 
African Americans accounted for almost 30% of 
the TB diagnoses for females aged 15-44 years 
(white females accounted for 10%). Slightly more
cases occurred among African-American and white 
women aged 36-44 years than among those who were 
younger (15-25 years).
Hispanic W om en
For many of the diseases discussed in this profile, 
higher prevalence rates among women of reproductive 
age are common not only among African-American 
women but also among Hispanic women. The factors 
that contribute to health disparities among Hispanic 
women are numerous and can include socioeconomic 
status, cultural norms, the use of injection drugs, and 
coinfection with diseases that disproportionately affect 
Hispanic women.
One in five Hispanics lives in poverty. Thus, this 
population faces many socioeconomic challenges 
that can put them at increased risk of disease, 
including a lack of formal education, employment, 
transportation, and health insurance, all of which can 
compromise the receipt of high-quality health care, 
increase the likelihood of disease, and affect health 
outcomes. Cultural traditions and beliefs also affect 
health. For example, in the Hispanic community, the 
cultural concept machismo—the belief that all men 
should assume strong, protective, masculine roles 
as providers for their families—likely contributes to 
HIV transmission: the social pressures associated with 
this gender stereotype can cause men who have sex 
with men to hide their sexual behaviors from their 
female partners or fail to seek HIV testing. Machismo 
has been associated with other types of risky sexual 
behaviors, such as having unprotected sex with 
multiple partners that place women and men at higher 
risk of some STDs, including HIV infection.
Another contributor to disease prevalence is 
coinfection with diseases for which the rates among 
Hispanic women are high. For example, high rates of 
some STDs among Hispanics place these women at 
increased risk of HIV infection; similarly, elevated 
rates of HIV infection in this population can increase 
the likelihood that active TB disease will develop in 
Hispanic women who are coinfected with TB.
In 2007, Hispanic women accounted for 15% of 
females living with HIV/AIDS in the 34 states with 
mature HIV infection reporting systems, and in 2006, 
HIV disease was the fourth leading cause of death 
among Hispanic women aged 36-44 years. As is true
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of HIV/AIDS in African-American women, most 
cases in Hispanic women were transmitted through 
high-risk heterosexual contact with HIV-infected men. 
The second most common mode of transmission for 
this population was injection drug use.
In addition to higher rates of HIV/AIDS, the 2007 
rates of chlamydia, gonorrhea, and P&S syphilis were 
higher among Hispanic women of reproductive age 
than white women of comparable age. Specifically, 
the rates of chlamydia and P&S syphilis among 
Hispanic women were about twice the rates among 
white women, the rate of gonorrhea among Hispanic 
women was approximately 1.5 times the rate among 
white women. A comparison of the 2006 and 2007 
data indicates that among Hispanic women of 
reproductive age (all age subgroups), chlamydia 
increased in 2007, and gonorrhea decreased. The rates 
of P&S syphilis fluctuated slightly, depending on the 
specific age subgroup.
Hispanic women of reproductive age also are affected 
by TB to a greater extent than white women. In 
2007, among females aged 15-24 years, about 30% 
of reported cases of TB occurred among Hispanics, 
followed by 29% among those aged 25-35 years, and 
23% among those aged 36-44 years. Percentages for 
white females in the same age groups were 8%, 8%, 
and 14%, respectively.
Country of Origin
Reproductive-aged women who live in the United 
States but were born in certain foreign countries are 
at substantially higher risk of TB than are U.S.-born 
women. The incidence of TB among these foreign- 
born women has been increasing since CDC began 
collecting these data in 1986. Of the total number of 
TB cases reported among reproductive-aged women 
in 2007, Hispanics and Asians (U.S.- and foreign- 
born) accounted for two-thirds of all cases. Although 
the 2007 rates were higher among U.S.-born Hispanic 
women (2.1 cases per 100,000) than among U.S.-born 
white women (0.5 per 100,000), Hispanic women who 
were born in the United States are at substantially 
lower risk of disease than women born in Latin 
American countries. Even more significant is the 
rate of TB among U.S.-born Asian women: the 2007 
rate—3.0 per 100,000—was higher than the rates 
among Hispanic and white women.
A ge G roup
In addition to the racial/ethnic differences in disease 
rates among reproductive-aged women, there also are 
differences by age group. In 2007, younger women of 
reproductive age were disproportionately affected by 
each of the three most prevalent STDs. The highest 
rates of both chlamydia and gonorrhea were reported 
among females aged 15-19 years (3,005 cases and 
648 cases per 100,000, respectively), followed closely 
by females aged 20-24 years. P&S syphilis also 
disproportionately affected younger women in 2007: 
of the reported cases in women, most occurred in 
those aged 20-24 years. A diagnosis of TB, however, 
was more likely for African American and white 
women at the upper end of the reproductive age range 
(36-44 years) than for African American and white 
females at the lower end (i.e., 15-35 years) of the 
age range.
Conclusion
As shown by these data, the burden of disease is 
greater among reproductive-aged women, particularly 
those of some races/ethnicities (e.g., African 
American, Hispanic), those who are foreign-born, 
and those of specific age subgroups. Interventions 
specific to these women are crucial to the prevention 
and treatment of these diseases: untreated, many of 
these diseases can not only lead to more serious health 
problems in these women but also can be passed on 
to their infants. Examining the data on these diseases 
collectively is useful in determining disproportionate 
disease burden and in identifying ways to more 
effectively promote prevention and provide treatment 
services to reproductive-aged women.
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